THERAPEUTIC APPARATUS AND METHOD

Abstract: An apparatus and method for treating cancer and other illnesses in humans and animals are described. The treatment involves the low-power, pulsed application of radio frequency tuned with precision of at least one half part per million. Alternative embodiments are described for apparatus that generates the required RF signals and applies such signals therapeutically. Laboratory data is reported, showing the successful use of the disclosed apparatus and methods to suppress and eliminate cancerous tumors in mice.

Description: THERAPEUTIC APPARATUS AND METHOD FIELD OF INVENTION This invention generally relates to apparatus and methods for treating cancer and other illness in humans and animals, and more particularly to a therapeutic apparatus and method based upon the administration of precisely regulated, low power, pulsed electromagnetic radiation (EMR). BACKGROUND OF THE INVENTION There is a considerable body of early literature regarding treatment of various illnesses with radio frequencies (RF) in the 43 MHz range. In U.S. Patent No. 2,545,087, F. J. Hart disclosed an apparatus for treating a subject with a sequence of radio frequencies in the 43 MHz. range, applied in a stepwise fashion. These frequencies were each modulated sinusoidally at 60 Hz., and further pulsed by a second slow sinusoidal oscillator operating at 90 cycles per minute (1.5 Hz.). The RF frequencies employed by Hart were specified to three decimal places. The instruments available to Hart and the other researchers of his day were based on tube amplifiers, which resulted in oscillators with considerable drift that could not be precisely tuned. Hart's means for applying the RF energy to a subject most often consisted of a metal plate acting as an an- tenna. As a result of such oscillator drift and imprecision, and the inefficiency of the available output devices, Hart and his contemporaries were not able to conduct scientific tests with precisely controlled frequencies, or to discover optimal treatment modalities. Modern electronic technologies make it relatively simple to construct more precise and stable instruments than Hart had at his disposal. As a consequence, it has become possible to study systemati- cally the potential therapeutic value of EMR. The present inventors have undertaken such studies over the course of many years, and as a result have perfected apparatus and methods which have proved effective in treating cancerous tumors in laboratory mice. The inventors believe that the same methods can be effectively adapted for human treatment. The present inventors have constructed apparatus designed to overcome the limitations of Hart's approach. They have further sought to establish the utility of their invention through a program of animal testing, and have in turn used the results of such testing to refine the apparatus and the methods for effectively using such apparatus. The resulting apparatus and methods, and the experimental results of applying such apparatus and methods to treat cancerous tumors in mice, will be described below. SUMMARY OF THE INVENTION It is generally the object of the present invention to utilize electromagnetic radiation to provide effective treatments for cancer and other illnesses. It is a further object of this invention to achieve reliable and reproducible therapeutic results from EMR treatment methods by achieving precise control over the treatment frequency. It is also an object of the present invention to provide an efficient means of transmitting EMR from the generating means to the subject. It is another object of the present invention to provide an EMR treatment that may be applied at very low power levels that can cause no harm. These and other objects are achieved in accordance with the present invention through the use of an apparatus involving an oscillator that outputs, at a power of less than one mw, an RF frequency in the 43 MHz range, regulated and stabilized to the fifth or sixth decimal place, which is in turn modulated with a 60 Hz. 50% duty cycle square wave, which is in turn gated, again on a 50% duty cycle, at a rate of 1.167 Hz. (70 pulses per minute). The RF frequency is chosen for a particular subject based on the believed effectiveness of the frequency in treating the illness in question, as summarized herein. The modulated RF signal output by the apparatus of the present invention is applied to a flat loop of wire approximately 60 cm. long, grounded at one end and wound in five flat, concentric spiral- rectangular turns spaced about 3.175 mm. apart, the loop (herein referred to as a "treatment loop") be- ing mounted on an insulating layer adhesively bonded to a metal plate. In using this apparatus, the metal plate is placed, loop down, on the subject's body near the area to be treated. RF power is applied to the loop at one precise treatment RF frequency for at least one hour at a time. During treatment, the treatment loop is shielded from direct light and moving air currents. There are alternative embodiments of the invention that differ somewhat in their circuit and construction details. The first, referred to as the "Battery SCPO," is a battery-powered "Single Crystal Pulsed Oscillator" in a metal housing with an internal quartz crystal, and an integral, externally mounted treatment loop. Each Battery SCPO is limited to a single frequency. A variation is shown (the "Mouse SCPO") in which an SCPO is powered by an external DC power module rather than batteries. An alternate embodiment, referred to as the "Generator Embodiment", derives its treatment signal from the modulated output of a Hewlett-Packard Model 8662A frequency generator, and supplies the signal to the treatment loop over a short coaxial cable. The frequency and power of the Generator Embodiment is easily adjusted with controls on the front panel of the 8662A frequency generator. Another alternative embodiment, also based on the HP 8662A Frequency Generator, modulates the RF signal entirely externally to the HP 8662A, and employs a specific type of coaxial cable to carry the signal from the modulator to the treatment loop. These alternative embodiments differ somewhat in their circuitry and construction details, as will be more fully described below. In any of the alternative embodiments, treatment is non-restrictive and utilizes a low power believed to be completely safe for humans. Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention. BRIEF DESCRIPTION OF THE DRAWINGS FIGs. 1A and IB show top and bottom external views of the Battery SCPO. FIG. 2 is a block diagram of the major functional units of the Battery SCPO. FIG. 3 is a schematic diagram of the Battery SCPO. FIG. 4A shows the modulation waveform of the Battery SCPO. FIGs 4B through 4F show spectrum analyses of the output of the Battery SCPO. FIG. 5 is an external view of the components of the Generator Embodiment. FIG. 6 is a schematic diagram of the modulator circuit for the Generator Embodiment. FIGs. 7A and 7B show, respectively, the modulation waveform and a portion of the output waveform of the Generator Embodiment. FIGs. 8A and 8B show front and back views of the treatment loop used in connection with the Generator Embodiment. FIGs. 9A1 - 9J4 show the treatment housings and treatment loops used for treating mice in the experiments described herein. FIGs. 10 through 29 show, for each treated and control mouse involved in the inventors' experimental studies, A, the locations of the tumors (if any) that developed, B, plots (on a logarithmic scale) of the respective volumes of the various tumors as a function of time, and C, plots of the mouse's weight and hematocrit measurements as a function of time. FIG. 30 A and B shows bar graphs of the life spans of the treated and control mice, respectively. FIG. 31 A and B shows bar graphs of the life spans of the treated and control mice, respectively, after tumors were detected. FIG. 32 A and B shows bar graphs of the number of tumors in the treated and control mice, re- spectively. 3 SUBSTITUTE SHEET (RULE 26. FIG. 33 A and B shows bar graphs of the outcome with respect to the tumors found in the treated and control mice, respectively. FIG. 34 A and B shows bar graphs of the weight changes observed in the treated and control mice, respectively. FIG. 35 A and B shows bar graphs of the maximum size of tumors observed in the treated and control mice, respectively. FIG. 36 is a schematic diagram for an external modulator that attaches to the radio frequency output of an HP 8662A Frequency Generator and FIG. 36A is a top view of the exterior of the device. FIG. 37 shows, for a mouse treated with a Generator Embodiment pulsed externally by the modulator shown in FIG. 36, A, the location of the tumor that developed, B, plots (on a logarithmic scale) of tumor volume as a function of time, and C, plots of the mouse's weight and hematocrit measurements as a function of time. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 1. DESIGN CONSIDERATIONS According to experiments conducted by the present inventors, treatment with EMR is most effective under the following conditions: a) The treatment frequency is selected with a precision extending to the fifth or sixth decimal point, or at least one half part per million. b) The frequency is extremely stable over the course of the treatment. c) The precise frequency chosen is held at that frequency and applied without variation for at least one hour. d) RF power applied to the subject is held to less than one milliwatt (mW). e) The EMR is applied through a coiled loop of wire, which, for treatments in the 43 MHz. Range, is approximately 60 cm. long. The frequencies listed in Table 1 are believed to be effective for treating the indicated maladies: Table 1: Treatment Frequencies The foregoing list includes all of the frequencies studied by the present inventors and found to be effective. The inventors believe that different frequencies, even close to the above-stated frequencies are not effective. They have found that the effectiveness of the treatment depends critically on the precise frequency chosen, to the precision indicated herein. They have also found that steady tieatment frequencies are more effective than swept or varied frequencies. This invention is not intended to be limited to the frequencies stated in the above table. The inventors believe that there may be other frequencies in the 43 MHz. range that the present inventors have not as yet studied, that may also be effective. Similarly, the present inventors believe that there may be effective treatment frequencies in completely different ranges, for example, at much higher frequencies. The most important factor, in the view of the present inventors, is a precisely chosen frequency steadily applied for at least an hour at a time. 2. CONSTRUCTION OF ALTERNATIVE TREATMENT DEVICES For twenty years we have been working to obtain the correct frequencies with which to treat the mice and also the best possible instrument (method) with which to deliver the treatment to the mouse. Some of our experiments included using two plates (a hot and ground) rather than the treat- ment loop. All things considered, we feel the embodiments employing treatment loop electrodes have performed the best in our experiments on the mice. Detailed descriptions of the alternate embodiments of the invention are set forth here to demonstrate that the principles taught in this invention are readily reducible to practice. It should be understood that these embodiments represent but a few of the possible configurations of the present inven- tion, and that, utilizing the principles of the present invention as disclosed herein, analogous apparatus and methods may be readily devised for controlled therapeutic application of RF energy. A. Battery SCPO Top and bottom external views of the battery-operated embodiment of the treatment device are shown in FIGs. 1A and IB. The device 100 is built in a small, self-contained rectangular metal package measuring about 7.37 cm. long, 5.46 cm. wide, and 1.78 cm. in thickness. Housing 110 is preferably metal. It provides mechanical protection for the apparatus and serves as a electromagnetic shield. Housing 110 is soldered shut. In battery holder 114 (Caltronics BH-124) accessible from outside the package (and which may be recessed or attached to the exterior of housing 110), the housing accommodates four standard 1.5 volt "AA" alkaline batteries 115 of approximately 1.5 volts each, which provide the electrical power for the unit. The underside of the device, shown in FIG. IB, accommodates a surface mounted coil of wire 120 referred to as the "tieatment loop." One end of tieatment loop 120 enters the bottom housing surface through a wire feed hole 140 in the bottom of housing 110. The other end of treatment loop is grounded at solder point 150 to the outside of housing 110. The tieatment loop itself consists of five concentric, spiraled, rectangular turns of 20 AWG solid copper wire embedded in a 2 mm. (0.080 inch) thick sheet of high impact styrene 111 adhesively fastened to the bottom surface of housing 110. (Alternatively, the treatment loop may be constructed on a printed circuit board.) The windings are spaced 3.175 mm. apart and the overall dimensions of the loop are 2.858 x 5.258 cm. The treatment loop 120 has a broad radiating pattern off the coil. It is not a "focused" radiation but a spreading radiation. More signal is available from the front then off the back of tieatment loop 120 (the back is shielded by a ground plane). Tests were run using a loop without the back shield but the results were not as good as with a back shield. The signal is strongest in the center since that is where the "hot" lead connects to treatment loop 120 . The circuitry that drives treatment loop 120 is contained on a printed circuit board 190 (shown in the cutaway 180 in FIG. IB) within housing 110. The schematic for this circuit is shown in FIG. 3. The circuit comprises two timer circuits 210 and 240, which provide approximately a 60 Hz. approximately 50% duty cycle square wave, and an approximately 70 pulse per minute (1.167 Hz.) approximate 50% duty cycle square wave, respectively. These two square waves are combined in AND gate 260 in order to produce an approximately 60 Hz. square wave pulsed at approximately 1.167 Hz., each of the 60 Hz. Square wave and the 1.167 Hz. pulse having an approximate 50% duty cycle. The waveform output by AND gate 260 is shown in Fig. 4A. The output of AND gate 260 is then directed through filter 270, and then to quartz crystal XI 280. Although many frequencies could be chosen from, the Battery SCPOs built to date have used a crystal cut for a third harmonic frequency of 43.351830 + 20 Hz., 43.351850 ± 20 Hz., 43.351855 ± 20 Hz. and 43.351870 + 20 Hz. (corresponding to base frequencies in the 14.450 MHz range). These frequencies have been found most effective for treating a broad range of maladies. The output of crystal 280 is directed to tieatment loop 120. Viewed in further detail, the schematic diagram in FIG. 3 shows the power for the circuit derived from the four cell battery 301. This power supply feeds positive rail 302 and ground rail 303. The approximately 60 Hz. timing circuit 210 is based on a low power TLC 555 timer U2 311, set up as an astable multivibrator by connecting pins 2 (Trigger) and 6 (Threshold) together. Pin 1 is connected to ground 303. Pins 4 and 8 are connected to the positive supply rail 302. Pin 5 is connected to the midpoint of a voltage divider comprised of IK resistor R9 317 (this, and all other fixed resistors referred to herein being 5%, V. Watt, unless otherwise specified) from the positive supply and 2.2 K re- sistor R8 325 to ground 302. Pin 6 is in addition connected to 1N914, 75 PIV, switching diode D2 319 forward biased from pin; to 0.22 uF (50 volt) electrolytic capacitor C3 327 to ground 303; to 47K resistor R5 321 to the wiper of 20K, 15 turn, 3/4 watt adjustable resistor R7 323, one end of which is open and the other end of which is connected to pin 7. Pin 7 in addition is connected to 33K resistor R4 313 to the wiper of 20K, 15 turn, 3/4 watt adjustable resistor R6 315, one end of which is open and the other end of which is connected to the positive supply rail 302. Pin 3 is the output. The square wave frequency and duty cycle produced by 555 Timer U2 215 are adjusted by 20K, 15 turn, % watt adjustable resistors R6 315 and R7323 in accordance with the following formulas: tl (output high) = 0.693 x (R4 + R5 + R6 + R7) x C3 t2 (output low) = 0.693 x (R5 + R7) x C3 T (total period) = tl + t2 f (frequency) = 1/T D (duty cycle) = (R5 + R7)/( (R4 + R6) + 2 x (R5 + R7) ) (Units: R - Ohms; C - Farads; t, T - Seconds, f - Hz.) The exact frequency and duty cycle of this square wave varies with the battery voltage and precise component values The 60Hz. and 50% duty cycle figures required for successful operation of the preferred embodiment are believed to be plus or minus 10%, based on the condition of the batteries, exact component characteristics and environmental factors such as ambient and operating temperature. The 1.167 Hz (70 pulse per minute) timing circuit 240 is similar to that of circuit 210. The approximately 1.167 Hz. timer circuit 240 is based on a low power TLC 555 timer U3 341, set up as an as- table multivibrator by connecting pins 2 (Trigger) and 6 (Threshold) together. Pin 1 is connected to ground 303. Pins 4 and 8 are connected to the positive supply rail 302. Pin 5 is connected to the midpoint of a voltage divider comprised of IK resistor R14 347 from the positive supply and 2.2 K resistor R15 355 to ground 303. Pin 6 is in addition connected to 1N914, 75 PIV, switching diode D3 349 forward biased from pin 7; to 10.0 uF (16 volt) electrolytic capacitor C4 357 to ground 303; to 47K resistor Rll 351 to the wiper of 20K, 15 turn, 3/4 watt adjustable resistor R13 353, one end of which is open and the other end of which is connected to pin 7. Pin 7 in addition is connected to 33K resistor R10 343 to the wiper of 20K, 15 turn, % watt adjustable resistor R12 345, one end of which is open and the other end of which is connected to the positive supply rail 302. Pin 3 is the output. The output voltage of both TLC 555 timer circuits 210 and 240 is approximately 4 volts, which varies with battery supply voltage. The approximately 1.667 Hz. signal is combined with the approximately 60 Hz. signal in AND gate 260 which consists of 330 Ohm input resistors R2 367 and R3 367, and MPS2907 PNP transistors Ql 280 and Q2 290. FIG. 4A shows the waveform output from AND gate 260. From the output of the AND gate 260 is a 2.15K resistor Rl 369 in series with 2 ma red light emitting diode (LED) Dl 117 (Radio Shack 276-044 or equivalent) forward biased to ground 303. The LED is visible on the outside of housing 110, and is in the circuit merely to provide a visual indicator that the Battery SCPO is operating. The remainder of the circuit consists of 8.2 mH inductor L2 371 (Miller 8230-18), 5.5-18 pF trimmer capacitor C2 372 (Sprague-Goodman GY A22000 or equivalent), quartz crystal XI 280 and treatment loop LI 120 to ground 303. Crystal XI 280 is cut so as to have a base frequency in the 14.4 MHz. Range, and a third harmonic at one of the following frequencies: 43.351830 ± 20 Hz., 43.351850 ± 20 Hz., 43.351855 ± 20 Hz and 43.351830 ± 20 Hz. Quartz crystal 280 is obtained from International Crystal Manufactures, P.O. Box 26330, Oklahoma City, OK 73126, and selected with great care. Other sources for crystals that have been used include CTS Corporation, Knights Division, 400 East Reimann Ave., Sandwich IL 60548 (which is no longer in business) and NEL Frequency Controls, Inc. 357 Beloit Street, Burlington WI Crystals are ordered approximately 25 - 50 at a time for each frequency, and are then individu- ally tested on a Saunders Crystal Test System so as to allow selection of crystals with the desired fre- quency characteristics. For one representative crystal, driven with a reference frequency near the expected series resonance frequency, with a drive level of 2060 u Watts into 44 Ohms, with a 10 pF ca- pacitative load, the results of this testing were as shown in Table 2. Table 2: Exemplary Crystal Measurements No oven is used in this device. Instead, the unit is turned on for 10 minutes before use, and used in a room at an ambient temperature of approximately 72 degrees Fahrenheit. The output portion of the Battery SCPO involves a series LC circuit, a series crystal, and the tieatment loop, which is another inductor. The large Motional Inductance of the crystal, and its very small Motional Capacitance, dominate the output circuit. This is driven by the square wave train com- ing out of AND gate 260. The modulation waveform output from AND gate 260, measured at the collector of transistor Q2 365, as shown in FIG. 4A, has a rise time of 18 nS and fall time approximately 120 nS. To a reasonable approximation, each 60 Hz. cycle in the modulation waveform represents a 4 volt step input with the aforementioned rise and fall times, into a series LC circuit with low series resistance. The high frequency components of the steep rise and fall of this square wave stimulates a ringing of the crystal at its characteristic base frequency and harmonics. The actual output of the Battery SCPO at the point of input to Treatment Loop 120 can be observed on an oscilloscope, and visibly contains RF frequencies. This was observed using an SCPO constructed with a 43.351870 Hz. Crystal. When the signal from the SCPO was input into a spectrum analyzer, a -75 dB peak is observed at the 14.448461 MHz. base crystal frequency, and a -85 dB peak is seen at the 43.351870 MHz. third harmonic frequency of the crystal. An additional, weaker RF signal is observed at 43.420000 MHz. These various spectrum analyzer scans are shown in FIGs. 4B through 4F. In sum, rather than using a conventional crystal oscillator circuit, the battery SCPO uses a crystal series driven by audio range square wave mput pulses, m order to generate low power, yet precisely tuned, pulsed RF energy. The treatment device is used by applying it, treatment loop down, to the sub j ect's body in the area desired to be treated. The unit is left in place for approximately one hour at a time. As mdicated above, battery SCPOs have been built with crystals tuned to 43.351830 ± 20 Hz., 43.351850 ± 20 Hz., 43.351855 ± 20 Hz and 43.351870 ± 20 Hz. These frequencies were chosen because they are each believed to be useful for treating a plurality of illnesses, and because a multipurpose device is advantageous by reason of the inconvenience of changing crystals. However, there is no reason why this embodiment, would not be effective at any of the frequencies identified above as being therapeutically useful, as well as, with an appropriately tuned output element, if necessary, at any frequency found in the future to be therapeutically useful. A parts list for the Battery SCPO is set forth in Table 3. Table 3: Parts List for Battery SCPO B. Generator Embodiment The alternate embodiment of the treatment device is shown in FIG. 5. It employs a model 8662A frequency generator 500 manufactured by the Hewlett-Packard Company. Frequency generator 500 has a modulation input 520, to which is connected modulator unit 540, which provides an approximate 60 Hz square wave with an approximate 50% duty cycle, which is in turn gated with an approximately 1.167 (70 pulse per minute) square wave, also with an approximately 50% duty cycle. The circuitry of modulator unit 540, which is more fully described below, is similar to that of the Battery SCPO, up to the point of AND gate. As shown in FIG. 6, power is provided by a plug-in DC power module 550, Radio Shack Cat. No. 273-1455C or equivalent, which is rated at 9 volts D.C. at 0.3 amperes. The positive lead from the module is switched through power switch SW1 542, and then directed to a 7805 5 volt voltage regulator Ul 605. The negative lead of the supply is attached to the unit's ground rail 603. Both the input and output of voltage regulator Ul 605 is bypassed to ground by a 0.01 uF, 500 volt disc ceramic capacitor, Cl 606 and C2 607. The output, a regulated 5 volts, is applied to positive supply rail 602. The circuitry associated with the TLC 555 timers 611 and 641 is shown in FIG. 6, and is identical with the corresponding circuitry described above in the context of the Battery SCPO. The reference numerals "611" through "657" in FIG. 6 correspond to the identical elements "311" through "357" in FIG. 3. The AND gate of the modulator for the Generator Embodiment is configured identically here as in the Battery SCPO. R2, R3, Ql and Q2 (661, 663, 665, and 667) have the same values as in the SCPO circuit (361, 363, 365 and 367). The LED indicator circuit Rl 669 and Dl 541 differs from its counterpart in the Battery SCPO in that Rl 669 is 330 Ohms rather than 2.15K. The resistor difference is for the purpose of obtaining the proper LED brightness in each circuit. Adjustable resistor R17 677 provides a voltage divider between positive rail 602 and ground 603. The wiper of R17 677 provides a positively offset "ground" for purposes of output to the HP 8662A. The reason for this is that the HP 8662A expects an DC signal for purposes of modulation, so this adjustment is provided to offset the output around "zero volts" as referenced to the chassis of the HP 8662A. The output of AND gate at the emitter of Q2 665 is connected to 8.2 uH inductor L2 671 (Miller 8230-18). The resultant signal is bypassed to ground by a relatively large electrolytic capacitor, 1.5 uF, rated at 35 volts C5 673, and then passed to the center lead of output BNC connector 521. The approximate modulation waveform produced by modulator unit 540 is shown in FIG. 7A. The rounding of the rise and fall of the waveform is the result of capacitor C5 673. The modulated waveform of one of the 60 Hz. cycles output by the HP 8662A is shown in FIG. 7B (the RF component in this figure is not drawn to scale). The output power of the frequency generator is less than 1 mw. The output of frequency generator 500 is directed through a second BNC connector 531 connected to the panel of that instrument, and through a 50 Ohm, double-shielded coaxial cable 567 (RG 174 cable, Mouser #515-156-12 or equivalent). The coaxial cable is directed to a treatment loop 565 mounted on 2.0 mm. (0.080 inch) thick styrene sheet 566 which is laminated on stainless steel plate 560. The plate has dimensions of approximately 10.2 cm. by 6.35 cm. The treatment loop 565 is a 20 AWG solid copper wire approximately 60 cm. long, wound in a flat rectangular spiral comprising five turns, with a turn-to-turn spacing of approximately 3.175 mm. and overall dimensions of 2.858 x 5.258 cm. The center of the loop is soldered to the center lead of coaxial cable 567. Shield 863 of coaxial cable 567 is soldered to the back of plate 560 at solder point 861. The outer end of tieatment loop 565 is grounded by being soldered at solder point 570 to the loop side of plate 560. (Use A and B figures to show both sides of the plate. The signal from the frequency generator based embodiment of the treatment device is stronger electiomagnetically than that output by battery operated device 100. It is also characterized by having only a single pure RF component at the desired frequency in the 43 MHz range. The treatment loop of generator embodiment is applied to the subject in the same manner as in the case of the battery powered embodiment. A parts list for the Generator Embodiment is set forth in Table 4. Table 4: Parts List for Generator Embodiment C. Alternative "Mouse SCPO" for Mouse Studies For purposes of the mouse studies described below, an alternative embodiment of the treatment device was developed, hereinafter referred to as the "Test Embodiment". The Mouse SCPO consisted of an apparatus similar to the battery SCPO described above, but without a battery compartment, and powered by an external AC power adapter. The power adapter used was the same Radio Shack adapter 550 used with the modulator for the Generator Embodiment. The power supply circuit in the Mouse SCPO was identical to that used in the modulator for the Generator Embodiment, comprising the 7805 regulator Ul 605, and the two 0.01 uF bypass capacitors Cl 606 and C2 607. In all other respects, the Mouse SCPO was as shown in FIGs. 1, 2 and 3, using the components listed in Table 4. The feature lacked by the Mouse SCPO is the lack of restraint resulting from not being tethered by a wire. However, in the case of treating mice, this feature is irrelevant, since the mice must be immobilized for treatment in any event. On the other hand, the Test Embodiment had the advantage that it had no batteries to run low and to be checked and replaced. D. Externally Pulsed Generator Embodiment A further alternative embodiment of the treatment apparatus was developed, herein referred to as the "Externally Pulsed Generator." The Externally Pulsed Modulator embodiment is identical to the apparatus shown in FIG. 5, except that (1) the modulator does not attach to the Modulator Input of the HP 8662A, but rather attaches directly via a BNC connector to the RF output of the HP 8662A, (2) the modulator externally modulates the RF signal and does not utilize the internal modulation circuitiy provided by the HP 8662A; and (3) the cable used to connect the modulator to the Treatment Loop is a specific type of coaxial cable, i.e., a Hewlett-Packard 10501A, 50 Ohm coaxial cable approximately 1.1 meters long. The modulator in the Externally Pulsed Generator embodiment contains a series solid state RF switch and associated connectors, which is pulsed by a pulsing circuit identical to that shown in FIG. 6, except that potentiometer R17 677 and capacitor C5 671 have been removed and the ground is taken from the main power supply ground rail 1303 (corresponding to rail 603 in FIG. 6). (Since there is no need to mterface with the modulatoi input of the 8662A, there is no need for the floating ground used in the output cncuit of FIG 6 ) The schematic diagiam m FIG 36 shows the entire circuit of this external modulator In Fig 36A, which shows the exterior of the device, shielded box 3601 is attached to the end of modulator housmg 3600 Male BNC connectoi 3610 attaches directly to the RF output of the 8662A Female BNC connector 3620 attaches to the 10501 coax which m turn leads to the Treatment Loop (Since this unit is a self-contained external modulatoi, it is necessary to turn off the modulation mternal to the HP 8662A usmg the switch for that purpose on the control panel of the HP 8662A ) In the RF switching circuit, the output of mductor L2 3671 is a 60 Hz/1 667 Hz waveform 3640 (also as shown in FIG 7A) This waveform shifts the bias on D43651 and D5 3652 so as to switch the RF applied to mput 3653 in accordance with the pulses from L2 3671 In addition, mductor L2 3671 serves in this circuit as an RF choke keeping excessive RF from gomg back mto the pulsing circuitry Table 4A: Additional Part for Externally Pulsed Generator Embodiment 3. EXPERIMENTAL PROCEDURE AND RESULTS A controlled set of expenments weie conducted durmg 1995 and 1996, to June 25, 1996, to test the utility of the piesent invention with respect to the suppression and elimination of cancerous tumors, cysts, lesions, and neoplasm The experiments were performed upon mice, by the topical application of electromagnetic (EMR) ladiation at specific frequencies and intensities on a regular schedule, usmg the apparatus of the piesent invention as adapted for applymg EMR to mice We also present some addi- tional measurements taken m 1997 with respect to one mouse that was treated usmg the Externally Pulsed Generator Embodiment "Suppression and elimination" means that tumors, etc that do develop are smaller m size, occur relatively mfiequently and aie likely to disappear over fame, as opposed to unfaeated tumors that are larger m size, occui more frequently and are unlikely to disappear before the death of the subject Use of TAX Mice as Experimental Subjects The Tackson Laboi atory at Bar Haibor, Mame, 04609 supplies mice for scientific research These special mice aie "JAX Mice," of a special inbred breed identified as C3H HeOuT These mice are highly abnormal, in that they aie inherently very susceptible to adenocarcmoma of the mammary gland, due to the contributing factois of heiited genes, excessive hormonal stimulation, and the mouse mammary 14 SUBSTITUTE SHEET 0.ULE 26) tumor virus, which is passed to the young through the mother's milk. The adenocarcinomas develop spontaneously in these mice, and the breed is characterized by a high incidence of mammary tumors by eight months of age. Our project has used "JAX Mice" type C3H HeOuT throughout all of its research for treatment of mouse tumors, including all of the treated and control mice referred to herein. The JAX C3H HeOuT mice were selected in order to provide a sensitive animal model for testing anticancer treatments. The effectiveness of various treatments for such tumors is measured by de ¬ termining improvements in lifespan or other physical characteristics, such as gross appearance, health status, and other related data, of groups that have received the tieatment, as against untreated controls. This manner of testing using JAX mice is accepted as a valid animal model for determining the pro- spective utility of cancer treatments in humans. In a memorandum dated March 18, 1997, The Jackson Laboratory notified users of C3H/HeOuJ that it had observed an alteration over time of the development and incidence of tumors in this strain. Our experiments were primarily conducted in a much earlier time frame than that concerned in this memorandum, and we do not believe any of our experimental results were affected thereby. Summary of Experimental Procedures and Results "Control" and "treated" selections of JAX mice (10 mice per group) were observed over the duration of their lives. Control mice were not exposed to the treatment procedure at all. The treated mice were exposed to EMR at the skin layer. The treatment given was exposure to electromagnetic radiation applied to the skin of the mouse, with the radiation held at a given frequency throughout the treatment. The duration of treatment was usually one-half to one hour, and during the treatment, the treating electrode was shielded from undue light and moving air currents. The data from our experiments, discussed in detail below, show that: 1. Treated mice live much longer than controls. 2. The life spans of treated mice compare favorably with life spans of normal (i.e., non- JAX) mice. 3. Treated mice have good health throughout their life. 4. Prior treatment has prevented abdominal tumor development. 5. When an abdominal tumor has been treated directly on the electrode it is caused to disappear. 6. By contrast: a) Tumors on control mice grow rapidly until death of the mouse, b) And as tumors grow, a control mouse gains weight, its hematocrit decreases and its health fails rapidly until death. Treatment of the particular mice herein discussed was by exposure of the JAX mice to radiation from an electrode which was energized by a low power source that was preset to provide frequencies of 43.351830 MHz, 43.351850 MHz and 43.351870 MHz. In some cases, an HP-8662A Signal Generator preset to these frequencies was used, equipped with a modulator (in all but the 1997 data, an internally coupled modulator), to provide approximately 1.667 and 60 Hz., approximately 50% duty cycle square wave pulse trains as previously described. In other cases, the same pulsed tieatment frequencies were obtained with the "Mouse SCPO" embodiment described above, which contained its own modulator circuit, driving an internal quartz crystal. The frequencies selected, as listed in the preceding paragraph, were based on prior experimen t s conducted over a period of many years, during which a large number of mice were treated under varying conditions and with various treatments. The three frequencies specified in the preceding paragraph are believed by the inventors to be among the most effective frequencies for treating a range of maladies. When using the Mouse SCPO embodiment, the treatment frequency used 69% of the time (659 hours out of a total of 950) was 43351870 Hz. When using the HP 8662A signal generator for treat- ment, many (35) different frequencies were used. Treatment Procedures One of the treated mice (OUJ-479) received treatments before a tumor appeared and lived and died tumor free. Treatment of the remaining mice started as soon as a tumor reached 0.07" in length, width, and height, corresponding to an ellipsoid having a volume of 0.0295 cubic cm. (0.00018 cubic inches). The treatments for all these ten mice were every day except Sunday. The treatment frequencies are limited to a few specific frequencies within a narrow range, and the intensities are normally set to 0 dBm into a 50 ohm load. Due to variations among individual mice (as in other species, including humans), a treatment configuration that is effective for one subject doesn't always work for another. Frequencies of 43.351850 MHz and 43.351870 MHz were used for standard tieatment on almost all of the mice. These frequencies have demonstrated good results. Treating mice with 43.351850 MHz from a signal generator and/ or pulsed crystal, appears to clear up their secondary infections, and treating with 43.351870 MHz seems to restore their general health. All of the treated mice appeared to be very lively and have a very healthy skin and hair appearance. Of the mice listed below, all hematocrit values have stayed in the healthy range of 38% to 46%, and their weight basically stayed the same since they began treatment. Hematocrits for both the treated and the control mice were measured in accordance with the following procedure. The hematocrit was taken once a week. The mouse was placed under a heat lamp for a few minutes to cause the veins in the tail to dilate, thus making it easier to extract the blood for the sample. The amount of blood taken was about one-half of the standard 75 mm long capillary tube. The capillary tubes containing the blood are spun in a Micro-Hematocrit Centrifuge, at its "number three" marking. The capillary tubes are removed and placed in the Micro-hematocrit Tube Reader, which gives the percent of red blood cells found in the sample. We have observed that tumors that have reached 0.07" in length, 0.07" in width, 0.07" in height are definitely a malignant growth, and benign or cystic lesions can be ruled out. Neoplasia measured under the agreed size are questionable. Almost all of the neoplasia encountered measured 0.07", 0.07", 0.07" and above. The treatments employed a variety of treatment electrodes and housings, as shown in FIG. 9. The preferred housing was the "E" housing shown in FIG. 9A, and the preferred electrodes were the "I" electrode associated with the Mouse SCPO, FIG. 9J, and the "F" electrode used with the Hewlett- Packard signal generator, Fig. 9B. Tumors treated directly on the treatment electrode slowly regressed until they were gone. Tumors that were not on, or only partially on, the electrode showed a decrease in growth rate, but the tumor would steadily grow and not regress back The electrode was re-designed so that any tumor could be treated. The tumor must be directly on the electrode to receive the maximum treatment needed for complete regression of growth. Mice with lesions on their abdomen had direct contact with the electrode, and all completely regressed back to zero. We've had similar success with some mice with lesions on the neck, left leg, right neck, right side, etc. Since mammary tumors occur spontaneously in these mice, some mice were also treated before any tumors appeared in the hope of preventing the inevitable fate of the cancerous C3H strain, which have an almost 100% occurrence rate. At present one of the mice lived out its life span tumor free and died of old age. Treated Mice The following describes our experimental results with respect to each individual treated mouse. For each mouse, there is a corresponding drawing showing where on the mouse tumors appeared, and in which the tumors are identified by a "tumor number" T-X, as well as a drawing reference numeral; a graph showing tumor volume in cubic inches vs. time in days; a graph showing mouse weight in grams and hematocrit readings vs. time in days; and an Appendix setting forth all experimental measurements taken with respect to the mouse. Each tumor growth graph (FIGs. 10B, 11B, etc.) shows the size of each tumor, in cubic inches, on the mouse in question as a logarithmic function of days after the appearance of the subject's first tumor. Tumor volume, in cubic inches, was calculated based on the assumption that the tumor was approximately an ellipsoid, and had a volume equal to 1/2 length x 1/2 width x height x 2.094. Each weight and hematocrit graph (FIGs. IOC, 11C, etc.) shows, in two separate plots, (a) the weight of the mouse, in grams, and (b) the subject's hematocrit values (percentage of red blood cells) as a linear function of days after the appearance of the subject's first tumor. The detailed data collected with respect to each treated mouse is shown in tabular form in Appendices A-l, A-2, etc. attached hereto, and the data collected with respect to each contiol mouse is shown in tabular form in Appendices, B-l, B-2, etc. attached hereto. The data with respect to one mouse tested in 1997 is shown in tabular form in Appendix C. Example 1 - Treated Mouse OUJ-456 Table 5: Treatment Summary for OUJ-456 This mouse lived 219 days before any tumor appeared. Notice (in FIG. 10B) that T-2 1002, which was hard to reach with our electrodes, grew, but at a slower rate than a typical contiol mouse. As will be seen from this and the other examples herein, treated mice live three times longer than controls after a tumor appears. Example 2 - Treated Mouse OUJ-470 Table 6: Treatment Summary for OUJ-470 This mouse lived 258 days before any tumor appeared. Notice (in FIG. 11B) that T-l 1101 appeared and went away at two different times. T-2 1102 appeared for a short period. T-3 1103 appeared when this mouse was 496 days old. This is one of the longest-lived mice in our experiments. Example 3 - Treated Mouse OUJ-471 Table 7: Treatment Summary for OUJ-471 This mouse lived 305 days before any tumor appeared. Notice that T-l 1201 and T-2 1202 appeared for a short period. Notice (in FIG. 12C) the steady weight at 30 grams and constant high hematocrit percentage readings. This was also one of our longest-lived mice. Example 4 - Treated Mouse OUJ-473 Table 8: Treatment Summary for OUJ-473 As an experiment, we treated this mouse before any tumors appeared. This mouse never developed any tumors (FIG. 13B). She lived 303 days before we started tieatments. Notice (in FIG. 13C) the steady weight at 28 grams. This was also one of our longest-lived mice. Example 5 - Treated Mouse OUJ-475 Table 9: Treatment Summary for OUJ-475 This mouse lived 258 days before any tumor appeared. Notice (FIG. 14B) that T-l 1401 and T-2 1402 appeared for a short period. Notice (FIG. 13C) the steady weight at 30 grams and quite-constant high hematocrit percentage readings. This was also one of our longest-lived mice. Example 6 - Treated Mouse OUJ-496 Table 10: Treatment Summary for OUJ-496 This mouse lived 267 days before any tumor appeared. Notice (FIG. 15B) that T-l 1501and T-5 1505 appeared and left. Notice (FIG. 15C) the steady weight at 30 grams and high hematocrit percent- age readings. Even with all these tumors, this mouse stayed healthy until the end and lived a long time. Example 7 - Treated Mouse OUJ-506 Table 11: Treatment Summary for OUJ-506 This mouse lived 287 days before any tumor appeared. Notice (FIG. 16B) that T-l 1601 , T-2 1602, and T-3 1603 appeared for a short period. After 170 days, T-2 1602 reappeared. Notice (FIG. 16C) the constant high hematocrit percentage readings. This was our longest-lived mouse, and it had a long healthy life. Example 8 - Treated Mouse OUJ-516 Table 12: Treatment Summary for OUJ-516 This mouse had a record number of tumors, many of which were not on the abdomen (FIG. 17A). After tieatment all tumors disappeared except T5 1705, T71707, T8 1708, and T9 1709 (FIG. 17B). In spite of the large number of tumors, she lived 418 days. Example 9 - Treated Mouse OUJ-526 Table 13: Treatment Summary for OUJ-526 This mouse had three tumors which disappeared and never returned (FIG. 18B). She lived 267 days before any tumor appeared. T4 1804 and T5 1805 grew together as one tumor. Hematocrit percent (FIG. 18C) stayed quite high throughout her life. Example 10 - Treated Mouse OUJ-650 Table 14: Treatment Summary or OUJ-650 This mouse had three tumors, all of which disappeared and never re-appeared (FIG. 19B). Her hematocrit percent and remained high and her weight stayed constant throughout the measurement period (FIG. 19C). Control Mice The controls listed below all had spontaneous occurrences of multiple tumors that arose in various areas of the mammary gland region, and also had a very short survival time once the tumors appeared, usually around a two-month period. None of the control mice in this study received EMR treatments or any other type of intervention methods. Daily weight and tumor measurements and observations were noted, as well as hema- tocrits to indicate the mouse's present health status at the time. These non-treated mice appeared to be in excellent health and appearance when the tumor remained small and didn't metastasize, but as the malignancy progressed and spread to other tissues, the effects on the mouse were readily seen. The tumor measurements showed a rapid increase in tumor size that continuously rose almost every day, accompanied with a steady gain in weight, especially, with the arrival of new neoplasms. The hematrocrit steadily lowers with the increase in tumor measurements. Other side-effects were also observed in the controls, such as, the coat began to show a rougher appearance, the back bone protruded out, they appeared to be malnourished, and the normal curiosity and physical activity seen in healthy mice were absent. The neoplasms' appearance also changed once the tumor reached a certain size, usually around 1.5 cm. in diameter and up. They usually would start to appear red and puffy, which would deepen in color showing areas of purple and black sores, which eventually ulcerated with severe bleeding. Some of the mice also appeared to get secondary infections once the tumor ulcerated, accompanied by the draining of clear fluid and WBC present in the wound. When the tumor reached a diameter of 1.8 cm., and the hematocrit value was 25% or lower, the mouse usually died within a couple of days. As will be illustrated by the experimental data that follows, the characteristics of all control mice observed in the lab included the following: a rapid growth rate of tumors shown in the increasing size measurements and weight gain; metastasis; and continual decrease in hematocrit with the increasing tumor measurements. All the above symptoms affect the mouse's gross appearance, tumor appearance and shortened survival span once the tumors appear. This is reflected in the data that follows in the controls' rate of growth, and their decrease in hematocrit and length of survival period. Example 11 - Control Mouse A-486 Table 15: Summary for A-486 This mouse had one tumor which grew very rapidly to a large size (FIG. 20B). She had another tumor which appeared for 8 days. Her weight started to increase near the end, and the low hematocrit readings indicated a poor general health (FIG. 20C). Example 12 - Control Mouse A-488 Table 16: Summary for A-488 This mouse had one tumor (Tl 2101) which didn't change much for forty days then grew rapidly (FIG. 21B). T-2 2102 came in and left after 32 days. T-3 2103 stayed constant in size for about 90 days, then grew rapidly. Example 13 - Control Mouse A-490 Table 17: Summary for A-490 This mouse had four rapidly growing tumors and lived only fifty days after the first tumor appeared (FIG. 22B). After 20 days her weight increased and hematocrit reading steadily dropped (FIG. 22C). Example 14 - Control Mouse A-492 Table 18: Summary for A-492 At 375 days, this is the longest lived contiol mouse. (Nine of our ten treated mice lived longer.) She had two tumors that left (FIG. 23B). But, after thirty days, T3 2303 and T4 2304 appeared and started to grow very rapidly. Her hematocrits dropped rapidly after 70 days of measurements (FIG. 23C). Example 15 - Control Mouse A-500 Table 19: Summary for A-500 This mouse did not live very long and was observed only twenty-six days then she died. Tumors grew rapidly (FIG. 24B) and hematocrits were quite low (FIG. 24C). Example 16 - Control Mouse A-538 Table 20: Summary for A-538 This mouse had three large tumors (FIG. 25B) and rapid weight increase and very low hematocrit percent readings (FIG. 25C). This mouse also did not live very long and was quite unhealthy. Example 17 - Control Mouse A-540 Table 21: Summary for A-540 This mouse had one tumor that grew to a large size and grew fast (FIG. 26B). Low hematocrits caused this mouse to die in a short period (FIG. 26C). Example 18 - Control Mouse A-542 Table 22: Summary for A-542 This mouse had two tumors that grew to a large size and grew fast (FIG. 27B). Weight continued to increase as the tumors grew (FIG. 27C). A tumor size of 0.1 to 0.5 cubic inches on a mouse this small is quite a burden for the mouse. They do not survive for long with tumors that size. Example 19 - Control Mouse A-592 Table 23: Summary for A-592 This mouse had one tumor that grew to a one cubic inch in size and grew fast (FIG. 28B). Rapid decline in hematocrits caused this mouse to die in a short period (FIG. 28C). Notice the rapid increase in weight: the mouse nearly doubled in weight in twenty days. This was a very short-lived mouse. Example 20 - Control Mouse A-594 Table 24: Summary for A-594 This mouse also had one tumor that grew to a large size and grew fast (FIG. 29B). Rapidly declining hematocrits caused this mouse to die in a short period (FIG. 29C). This is one of the shortest- lived control mice of the group. Experimental Conclusions Our principal conclusion, based on the experiments described above, is that the cancer-prone JAX mice benefited considerably from the therapeutic apparatus and method of the present invention. The subsidiary experimental conclusions that support this assertion are as follows: 1. Total Days of Life: Treated Mice Live 50% Longer The bar-graphs in FIG. 30 show that the treated mice lived approximately 50% longer on average than the controls. Each bar indicates: Days of Waiting 3001, Days of Treatment (or Measurement) 3002, 3003, and Total Days Of Life 3004. The data underlying FIG. 30 (as well as FIGs. 31 and 32, discussed below) is presented below in tabular form. Table 25: Days of Life, Measurement, and Number of Tumors 2. Starting Treatment After First Tumor Appears: Treated Mice Live More than 300% Longer FIG. 31 shows that after the first tumor appeared, the treated mice lived longer than the control mice. The bars in these graphs represent Days of Treatment for treated mice or Days of Measurement for contiol mice. The data underlying FIG. 31 is set forth in Table 25 above. 3. The Treated Mice Had More Tumors (by 37%), But They Lived Longer FIG. 32 shows the number of tumors that developed in each mouse. It must be noted that even though there were 37% more tumors in the treated mice, they lived longer than the controls. The data underlying FIG. 32 is set forth in Table 25 above. 4. Tumors that Appeared were Five Times More Likely to Disappear in the Treated Mice than in the Controls. FIG. 33 shows the total number of tumors in each mouse, and those tumors that disappeared or were cured and the remaining tumors at the death of each mouse. (Note: OUJ-506 and OUJ-650 were still living as of June 25, 1996, when this data was compiled.) The data underlying FIG. 33 is set forth in Table 26 below. Table 26: Tumors That Disappeared 5. The Weight of the Treated Mice Remained Stable, Whereas the Control Mice Markedly Gained Weight FIG. 34 shows that the tieated mice maintain their weight on average, while the contiol mice gain considerable weight due to tumor growth. (Note: The weight change shown is the last 10 day weight average minus the first 10 day weight average of each mouse.) The data underlying FIG. 34 is set forth in Table 27 below. Table 27: Comparative Weight Changes 6. The Control Mice Had More Large Tumors FIG. 35 shows the maximum sizes of each tumor on the twenty different mice. Some of these tumors disappeared. The vertical scale is tumor size in cubic inches. There were 37 treated and 27 control tumors but this graph shows the 27 largest treated tumors and ll 27 control tumors. The data underlying FIG. 35 is set forth in Tables 28A and B below. Table 28A: Comparison of Maximum Tumor Size (in cubic inches) Table 28B : Comparison of Maximum Tumor Size (in cubic inches) Test of Externally Pulsed Generator FIG 37 shows the results of treating mouse OUJ-738 m 1997 with the Externally Pulsed Generator embodiment Treatment was with the HP 8662A frequency generator externally modulated with the modulator shown m Fig 36, coupled to a tieatment loop as shown m FIGs 8A and 8B deployed m the "E" housmg shown m FIG A The correspondmg experimental data is shown m Appendix C FIG 37A shows that a smgle tumor Tl 3701 developed on this mouse m the left arm position This position is difficult to treat because it is out of the way and as a consequence it is difficult to position the treatment electrode close to the tumor Nevertheless, the results with this mouse were extremely good for the period of testing As shown in FIG 37B, the tumor stayed small for the entire period, and as shown m FIG 37C, the weight was stable and the hematocrits remamed high The data ex- tends up to a few days prior to the filing of this application, and at the end of this period the mouse was alive and healthy. In addition, data were compiled in 1997 with respect to tumors that disappeared after treatment with the generator embodiment. This data, which otherwise appears in the Figures hereto, is as follows: Table 29: Disappearance of Tumors on Mice Treated with HP 8662A Frequency Generator Embodiment It is apparent from the foregoing that a new treatment has been developed which has shown great effectiveness in treating cancer and other illnesses in laboratory mice and is believed to be a promising treatment for humans. While only presently preferred embodiments have been described in detail, it will be apparent to those skilled in the art that certain changes and modifications can be made without departing from the scope of the invention, as defined in the following claims. APPENDICES Al - AlO TREATED MOUSE DATA Index (Pages numbered on back) Appendix Subject Pages Al OUJ 456 48-49 A2 OUJ 470 50-55 A3 OUJ 471 56-59 A4 OUJ 473 60-63 A5 OUJ 475 64-69 A6 OUJ 496 70-71 A7 OUJ 506 72-75 A8 OUJ 516 76-83 A9 OUJ 526 84-91 AlO OUJ 650 92-93 Surbeck, et al , Therapeutic Apparalus and Method OUJ-456- xls ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo /11/97 Page 1 OUJ-456- xls OUJ-456- xls ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo /11/97 Page 2 OUJ-456- xls OUJ-470-.xls Gr ooooo ooooo ooooo ooooo ooooo ooooo ooooo ε ooooo ooooo ooooo ooooo ooooo scPOei ooooo εcpo«ι ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo εcPO-1 ooooi ooooi εcP0*3 ooooi εcP0*3 ooooo εcP0*ι εcpo«3 ooooo ooooo ooooo ooooo εCPOei cP0«3 εcpoei εcpoo ooooo ooooo ooooo ooooo ooooo εc D θeι ooooo oooo ooooo /11/97 Page 1 OUJ-470- xlε X X X X X X Ϊ Ϊ X X X X X X X X I X X I I X I X I I X I Ϊ I I X I I I X X I I Ϊ Ϊ I Ϊ Ϊ Ϊ Ϊ X I Ϊ X ? ppppppp PPPPPPPP°P p p p p p _ _ _ ___ _ω_ ____; o ssssss ??ΪSS.?SSΪΪ?????553 X_ _:X-:-:-:-:- XXX-:IIXXI £ΪX XX IX £XXXIXIΪIX__XIXXX_X_XX __________________ Ills sisals! .3l 3 P- P P P P P ___l_._._._^SS_2_._2___._.__._.___;^ δδ »δ»δ"δ"δδδδδδδδ ""' ϊϊϊϊϊϊ? 5?5!; ?iS S"ϊK„s"ϊ-g>_.3saϊsss-Sossssϊsssϊ.sϊg SSRi_SSt;RSSSS!._R;S_S_t.SSSSRSSSSSSSSSSSi.loSSSSSSSSSF;SaS ra α. IoIoIo lllssssllls ___________ silssisiiil !.]l]!JllH--.HH.!]H....!i.i-..!!!..if..f!H!,iI OUJ-470- xls ooooo SCP0*3 ooooo SCP0β3 ooooo εCP0*3 ooooo εcpo«3 ooooo εc 0β3 εcPo»3 ooooo εcpo*3 ooooo SCP0e3 εcPo 3 ooooo SCP0«3 SCP0*3 ooooo ooooo εcpo*3 SCP0*3 ooooo ooooo SCP0e3 ooooo ooooo εcP0*3 εcPo*3 ooooo εcpoe3 εc 0*3 ooooo ooooo εcP0*3 ooooo ooooo εc 0β3 ooooo ooooo ooooo ooooo ooooo ooooo εcpoe3 ooooo ooooo εc oe3 εcpoes ooooo ooooo εcpoe3 ooooo ooooo εcpoe3 εcpoe3 ooooo ooooo εcpoe3 ooooo ooooo SCP0e3 εcpoes ooooo ooooo SCP0e3 ooooo ooooo εcpo«3 ooooo ooooo ooooo ooooo scpoeε ooooo ooooo SCP0S6 εcpoe3 __> o ooooo ooooo scpoeε scpoe3 ooooo ooooo εc o 3 ooooo ooooo SCP0*3 ooooo ooooo sc p o 3 ooooo ooooo εcPθe3 ooooo ooooo SCP0S3 ooooo ooooo SCP0*3 ooooo ooooo SCP0e3 ooooo SCP0e3 ooooo ooooo εcpoe3 ooooo ooooo εcP0«3 ooooo ooooo ooooo ooooo ooooo scPo 3 ooooo ooooo SCP0e3 ooooo ooooo SCP0e3 ooooo ooooo SCPO-3 scPoe3 ooooo ooooo SCP0e3 ooooo ooooo SCP0e3 scρoe3 ooooo ooooo εcPo 3 ooooo ooooo SCPOei scPo 3 ooooo ooooo εcpoei ooooo ooooo ooooo ooooo 4/11/97 Page 3 OUJ-470- xls X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X I X X -- X X X X X X X X X o _D o Oa OO_- Oθ- Oθ- -O-. O-L Oa. OQ. Oa. OQ. Oa O O-L Oa. OOa- OQ. O--. OCL Oa- O--- Oa O O-L O-L Oa OQ. O OQ- OQ. O Oa. O__L O_ OO OD_ OO O O O O O OOO O OO «o«υo W Wo uW tuO o_ o-O ot) oWW uW oW uoW oW oWoW o( uW oW υnWo(υ_ «υaW u0lo_ o-Oo_0 o« υ oυ o o o o uo υ o o o o u o υ o o i x x x ii i x x x x x x x x x x x x x x x x x x x x x x o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o sg;§sssfisϊ_!sa _ 5 -fϊsf;i;ϋss iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiin oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo σo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo ao σo oo oo oo oo oo oo 4] OUJ-470- xls ooooo εcpoei ooooo εcpoei ooooo εcpoeβ ooooo ooooo oooo ooooo ooooo εcpσ«3 ooooo ooooo εcP0«3 ooooo ooooo εcpoeε SCP0e3 ooooo ooooo ooooo ooooo εcpoeε scPo 3 ooooo ooooo εcpose scpoe3 ooooo εcpoee εcpo*3 ooooo εcpoeβ εc o 3 ooooo ooooo εcposε εcpoes ooooo ooooo εcpoee ooooo ooooo εcpoeε ooooo ooooo ooooo ooooo scpoee ooooo ooooo εcpoee ooooo ooooo ooooo ooooo ooooo ooooo εcpoe β ooooo ooooo εcpoeβ εcP0«3 ooooo ooooo εcP0*3 ooooo ooooo εcPθe3 ooooo ooooo scpoee SCP0*3 ooooo ooooo εcpoeβ SCP0S3 ooooo ooooo scpoee εcpo 3 -. ooooo ooooo εcpoee εcpo s ooooo ooooo εcpoeε εcP0«3 ooooo ooooo εcpoee SCP0e3 ooooo ooooo scpoeε SCP0*3 ooooo scpoeε εcP0«3 ooooo ooooo scpoeε SCP0*3 ooooo scpoei SCP0S1 ooooo SCPOei SCP0S1 ooooo SCPOei SCP0«1 ooooo SCPOei εcP0*3 ooooo SCPOei εcpoee ooooo o ιoo o ιoo scpoei εcpoeε ooooo scpoei ooooo scpoei ooooo ooooo o ιoo ooooo ooooo ooooo ooooo ooooo ooooo 4/11/97 Page 5 OUJ-470- xls OUJ-470- xls 8662A ooooo 8662A ooooo 8662A ooooo B662A ooooo 8662A /11/97 Page 6 OUJ-470- xls 3 O ixxxxx xxxxxxxixxxxϊxxxxxϊxxxixxxixxxxxxxxiϊii 5 ||I|I|||I|1|11II|I111|||oIoIo|o|o|oIo|oIo|o|o|oIo1oIS1o1oIS|oIoIαIαIoIo o s s : s x x i : B ιiiiSijiSli3SiJiiiSSSSii9!i8iSiiSSiSiiS8ii8iS5Sil! J S S 1 o _r * - ' -oooQoooooooooαooo Q θ ooooQ α αooα < -_ _3 o : e E E E ε ε E E E E E E E ε _. E E E E E ε _- E ε E ε E E ε _. E E ε E E E 6 E E E E ε ε t. E E ε E ε E E ε E E E ε oooooooooooooooooooooooooαo ϊiixxiϊiixϊ xxxxxxxxx xxxxxxxxxx xϊxxxix E E e E E E E E E ε ε E E E ε E ε E E E E E E e E E E E ε ε E E E E E E ε ε E E E E ε E e E E E E E E E E E E E E E .<<<< < < << << 3 O αooooσooooooo ooααooooooαooαooooo ooooooooooooooooooo OUJ-471-.xls oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo /11/97 Page 3 OUJ-471- xls 3 o XIXXXXIII XXXI XI IXXXXIIXIXXXII c Ex.Eo-EDαE)-EQEDάEιαEi-EθφE(EπEQffiε Eo-EoαE.αE__εoαEι_Eo_Eo_εDαε--εDmEαEi[Ei.cEQcEθ(E-i DoQoOoOooOQoQoQoOoδoQoDoQoQoOoQoQ< OooQoQoQoQoDoQoDoOoQoQoQo x-Ef ixxϊxxxxxxi-cxx xxxxϊ^ EεEEEEEEEεEEEEEEE EEEEEEεEEEE EE QQDQDOQαDQ_-QQ_-C_ClQαQ__D lDQαQQDQO $s;8 888! OUJ-473- xls ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo -. 0 ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo 4/11/97 Paαe 1 OUJ-473- xls 8S3lS|§8|SS8||888§8l|8|l§§18||8§^ o ιiHnH_ϊ--iιHHii--Hϊιϊ.ϊϊϊiιιϊιϊϊιiii_iiιιiiJiϊiiϊiiιϊϊi π u pp pppp βpgppopoooogo "PPPPPP PP! εssssssssspspppppi S 595 ! 135! 1111I11II11111111I111I11 ;1 a1 _ a < § s s § S S s _____J__<_<S <_:' < < < <<< < !_._> S! iϊϊϊlllllϋl ιxxxιϊ£ιιιιϊ-iϊxxxιϊϊxx ϊtϊϊx ϊx-ιrιxϊx_ϊιϊιϊϊι_ϊxϊ±x _ι _ϊ Sfisii 1|||||I|||||||||I|I||||I|I|||||||^ lώlsssssi e s s e 7 e e e e e < SSI i s a 9 s a a .' SUSS! < < _<<<< < iiiii o isRsas > eeeeeoseoe Rggggg !g eg SS Bg S sg S eggggggg iS S . g . § S9S iimum mn n : lass; OUJ-473- xls ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooa ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo /1 1 /97 Page 3 OUJ-473- xls 88|8|88888l88888|88.88.8.888888 _- o ϊϊxϊϊxϊϊϊϊiixxii f iixiiiiixiirxϊϊϊ liillii||||||||||l||||||||||l|||| sgggf≥ ;gigggigg§ggg- P P 999 P P ! --- .δδ -f xϊϊxxϊixϊixxϊϊixϊϊϊlϊixϊiiiϊϊϊ: iiiii iiiiiiiiiiiiiiiiiiiiiiiiii « < < < < < < .< : iδssss §§: •°1 Is _ i § - 33 =333 i s a s s s s a s a s s s s § ? ? . s o O o o o I 3 O σ % « « « « ** %«« ** y>oD-o_ δo.δδα.αδoαo_--oα.δα.δaoo-όD_δQ_δD-όQ.όG.o_Lόθ-όό_Lόo_ oo_Loόoόόaόaoo-LoQ.δoαδD_δQ δδ- δ_-.δδ---δαδQ.δδα uιoooouuooouoouuoou joo >u_.-θootJooot_ooυoo _t_o ouuυαuu X ιό CO —) CL D goo oo o o o o v o o o oo oo ooo o o o o o OUJ-475- xls ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo o ioo scpom ooooo o ιoo scpon SCPO*I ooooo ooooo ooooo ooooo ooooi OUJ-475- xls Page 2 OUJ-475- xls OUJ-475- xls ooooo ooooo ooooo ooooo ooooo ooooo ooooo scpoai ooooo ooooo SCPO*I ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo OODOO OOOOO ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo OUJ-475- xls Page 3 OUJ-475- xls __ o oαaoαooa oaδαoαoaoaoaaoooaoaoaoaaoδα oaoa oαaooaoα oa oaoαoaoa oaaooaoaoaaooaaooα oa oaoaoaoa oaαooa oaaooα oaoa υoooυooυoυoooυoooυυooυoυuoυooυoooυoooooυυoouoυooυoo o aaoaooaoaoa αooαoaoaoaδaoaoaoaoaoaoaoaoaoαoaoaoo.oaoa aooaoα oaoα oooooooooooooooooooo oooυooooooυυυoooo ooooooooooo oυ . aoaoaυaciαtj- Ω<jαoa αt>. aoaθa(- ct-jαooaoαoαoauoo- ?_ T !? ) o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o O oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo _) o i x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x i x x x x _> o •> £ oooo ooδ oo o o o o o o o o o oo o o oo oo oooo oo o o o o o o oδ o o o o o ooooo o a υ ao ao oα ao a a o- a α a a a a a a a a a a a a a a a ( ««υ oto o o«o(Λ oι o a a a a a a a a a o o o a a t Mo ot wυ a a a a a a a a a ao ao ao o o ao aυ oa t « o_. ow otΛ υt tυn«υ(υθ owwυow otoυ«ωoυωwoo(o ow ot tυo oo ow ot υw o o x i x x i x x -π x x x i x x x x x x x x x x x x x x x oa oa oa oa oa oa oa oa oa oα oa oa oa oa oa oa oa oa oa oa oaao oa oa oa oa oa oa oa oa oa oa oa oa o oa oa oa o oa oa oa oo- oa oa oa oα oa oa oa oα ooooooooυoυooooooooooυoυυuooυoououoυoυoooooυooooooo S, c? °- S S m S SS _. S p 5 m ≥ t 5 e ω ω ω ω *_- t o δ ω o δ δ - u « s * α a a a a a x x i x x x u « u « » « O O δ O O O a a a a a υ υ o o o o to CO co to t 10 o g____5?____? ?s5. -.-?. ????-.....-..-.. -. =- = :: = = = = " "'"____$ r'"'"-'?' » 5!l!!!:!!?! ιsiiilill§iililiiiliiiiiiliiiss55sssiis j tsfsi£sδs£i5iiiiiiiiiiiiiiiiiii£!if^iiii§iiif __!_________._ _S_-_-__ -- _ -- __-ε----__ -- __-^ l;iH!i. __..i!_ »« .i « .iiJ-i- !._.. « ,i » ...!__... ! _.H..!_.... » M! : - %ii4i4fliiiiiiii ii4ilUiliii|li |iIlllli lII4lli fiiSiiiiϊiiiiβϊ.... ____..__........__.ιι_.ιιι.ιιι_.__ii_. g ι g ϊiϊϊiiϊϊϊϊ««.ϊ..iiiiiiiBiii _i-iiiiiiiiiiliigiiiiiiiiiliBliBiiiiiiliBi } iiiiililiiiBig!ii__8_iiiiiiiBiiii___iiiiiii i >j; „ _5?^- S?5?_ „ ^g*;;; » ι «« ^^ι « ii^ a _ si _I I g gε ε p g i8ilSg88!BI!BSSaBBS!IB888BB8Bg§SiBiSgSl!!llBS£ilϋSδgε.lgiiSgiiiii£in!i§8iSiS3 ϊ!IIIII!l!I! l!I!!!I___!!I!!__________!_II____ III!!?_IIIII!s._l___I_______I!?_I?!!____!! !I!! III_II_I__IlI!_.__ I-!?____!_ _!?I_!I! I_IIl!!l giillililglliii&IIIIIlIϊMiiiϊibiiilliiiiillliiiyyillgliiiilllllϊIilliiii iiii - « ! ._..Jiiigi!iiiiii!iSiii!£ii!!!!iii!iiS!igiiiiii§iiii!!!iiiIiIIiiiilEEiiESiigiIigiSg!!I I |ιigigiigigggggg!!!!!g!ggggg£ππ!g£!!!i.gi!!!iπi!ili!!!ggiigggigggggggggggggigiggggggl f i^iϊIIIIiiIilIIIllililiIIllllill!SIlS2SSIllll2S_Sllllϊ_I5i-__g_i_lIIgIiii_.l 'IIIIllIiIlIi ?JSSCSϊ8fif!Br_fil!!.RR8ήHaX . . . gs__ϊn 1 _ 1 _ 1 _ _ 1 * _ I _ 1111 i I i _ 111111 PiI!iIIII__£_ggggggg_.g--gS8 n m m ζl .iltlllltlllillllltlliltlllt i4444i444444444444i444444444 ϊ≤_asi_≤sss-s§__§i-*ϊ§_s___aϊ !..-§.§.S-.gg....gg§3.gg.gg£ ii_ ssssss 8_8ϊϊ_ «_-_ϊ.ϊϊ S iiiiii! Illllilf ggggggg g___g_____ggg___ 3 _____•______ ____ __________a_g_g_ iO__g________ ____E_ ; « H--!!i!_g_-!£!£!S_£__!!! I* !__!_!!_!!!-_!£!!!!!!!!!!_] £ _ B»_-BBRSS_^S_8S8.„SS8SS„S "illili iillliiillillllEHi s__S§8SSS:S8?S_SS!S5?_!??**«_5 |*I!I!!II____-_-_-_-_-___-_l_ | E '!I_!_ -- __I_-eil___-_l_ --- !- ^li illliliiillilllilililii .'g!!!£!_!!_£££E£_!i!s£!S_£gg |>!i!!!!!E!§!SS2!!!a!!!!!SiSif s _6β*8S.B5«Ss88»9SS8SS88SΪ?5_ 5 .sassaaissasss asjsssβissgc J .S8 Ϊ . :S;; Ϊ -SSI;SS;ΪS;ΪΪ.SΪΪ.SJ: g°R8SRRR3RRf5RRRRRRRRRRRRR8KK;5K! iiiimimimiiiiiiiiiiimπiifiiiiiisiiiiiiiiiiiiiiif gϊ z 2_ .888 SglS- 888 _ 8Ϊ _gggg88_8g_S88. liillll! _ in lnl liillillllillill KS. ι * • ;_ I ξ SS38S__S8S$SS!JU!JiiJi!__________ „•____ __________ii___ i _ ΪSSBSS8SK8SS; .-•'-;s::;:t::sι;aι.;ι.i;i5!SS'»-' » "'--''S:55:. ϊt: 5SSUS5SSS b bbj. Ff Ff f F . . . . . . . . . . . . . . .. . . . . . PC. . . » » » . . . . . . . . . . . . . . . = . iij.il ^iϋjj- n ΪHHΪ mm __ιι i mm ^ ^ tn i n y* _____ itl±±± frl-fr ifiiii tiiU ϊiiiif iii iϊ ______ iffiii x±±ϊi lull iϋlϋ lllll » fiHiflililrii iiniiiiiiiii;ϋHϋϋi _H_E._'___ fl_l_filllill :____.___. ifiiHϋϋli! I' iHU HJHI iltitf film tttt±t tttϊϊt tttltt ______ ±lϊtϊt f±it± s_ lllll lllll i||iliii)iiiiii|iii iiiliiii Iiiiiiiiiiii ϊiiiiiiiiiij IllSIlIiIISIflS! m SΪSaΪ mm mm mm mm mm mm mm mm mi Ii i.g_HaSax8_8SRSS = SSϊSSEκaSBS88&888S8_S8B8..aS«. K?ΪSSSe!.8S_S8SKBSϊSllis: S28Sa88S§SSiiiESa888aa8Sa8S8B8l §ι iiiHiiiiiiiiiiiiSϋiiiiilϋfg- ^ Siii!ii§iiiiiiii3iiiSiiii§§5§i§ _-S_ϊ_l__S_i__|8S88i888888ii888lgS88i88888888888g88888888S8g88g88888g888S8 '^liliiliiiilsiiiiilliiiisiigiiiisiligiggiiiigggssissssisisiissglgsigisiis _ 2_ > .'-.l§ilig§8l§li§s§gigig§l§8l8l§l§l8lil_l8lSl8l8l8l8l8l-l-lSl-|8iS|8|_lSl8i8l_lgl_lgl_lgl8iglSl8l8lglgl8lglSlSlilglgig§glgl8l_§S§gi8§giSl§igi8i8igig f _ _ϊ si _ ∑_ g is___4444444444444444444444444444444_s_J||J.;t-___- _ βl . S!-«»« sjϋϋSSt-SSsϋassSRSSSi; ►... :::: S KCS Ϊ K S. S RS-BS-aSBaSS S S-ϊSSftSSlεSSϊSSBSISsHEJSS'-ϊS 8. ...... _ι m ssssss ssasss _ii__i ii- 1 * _ 3 ϊ I"> (88888i SggggSS 5 filiiiiiliiliiliilil ._ iiifs >, 8S8SS Iiiiiiiiiiii _ a _I i mm mm im im mmm H imim Ouj-506- xls _> o Ϊ888S 88888888 ;g _ ss ΪSgSΪ iss: SSSSi lllll! 9* illl ..SB! i88888S8S888Sg88S88888888888 D ΪS_ S: O 1S88888S ig S ϊ IgSf gϊ 3 o S8S5 S8888SΪ !8888l88g8 IS(Illi iiiiiisiiliilill 88888888888888888888888888! S8Si gggggggggiggggggssggggsMgg. 3 s iiiii isi ii 11 88 88 lllll!! S3SS88! 58888888881 ssgssss as 8888! iS8S888i §§§§§§! 8888! 888888: iiiil i i g i g i ; ■ s S35S233IISS3S3S8J2S85HSg3S3SIHIil _HHHII IHSSSSJJSiSS333« « :S___1___ __?_! OUJ-516-.xls 0 no 4/11/97 Paαe3 OUJ-516- xls l8 ieii ϋiiϋiϋiiiiiliiiiiiiliii assess iS._aa§888§§S8! !_S! _j 5 S8888! 188888888888! !SB8_8888Ϊ §1 ; . 8! S8888|8l8ϊ8_SS8 88 88 188 ! sli l8SS8il888 588_i 8 ! !?.__?__! , , , . , , 5 v * *• * v _• * ϊ rr rr r-r-r r-ϊ--r- r-r--- _" r r r- -"-"rt u - u ϊ u ^ u - u ^ u ^ o S XXXXXXX XXXXX XXXX ±XXXXXXXi ± X X XX XX t.'θeθeeC5eC. lϊC! ! xιxxx_-xιxxx£xxϊxxi_- ii##i###i###ii###########i###i# iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiliiiiiiiiiiiiisiiiiiiiiii liiiliiiiiiiiiiiiiiiiiliiiiiilliiiiiliiiliiiiiliiiiiiiiliiiiiiiii .. SiSSa.ϊ. SΪSS-JSC. gSSSϊSS.SSΪSSSSR.ISSSSSS .SSISSSSSSSSΪSJ-SM-;^ 'SSS!85BS55aS8558S!IS55S58!5SSSasSSS5!SSSSSS!5SSSS5SSSSSRSS_5SSSSR 3 O ,_S§§§iS888SS8S8888888888S888888888888S88888888888888 li88ll8iiillilili8§8lil8§l88888iiS§lill88_88§88li8Sg8g8g8l§l§ll8 _t _ »ff g.»»»g»«»5?§ , § , S , ?§ , ?????????S , ???§ , ?o.αo-αo.-.-.Q.ι *- τ _ 3 _ _ 33 . _ *< <J l << <*< *J < ' .<<< i< J . S Ϊ Ϊ ,l , ' ,l _ l OUJ-516-.xlε ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo oooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo Page 6 OUJ-516- ls oo oo o o oooo ooooo ....K.......PP..°....P..............i^ 3 m mmm m m m mmn iil__xi_-____------------ii£--------------_----rι__r___i-__ ####i#########iiii#####iiiii########iiii###ii##il5-#####i#i_l 5 __f__ixl_ϊ_-ixιιrϊr±iϊιjιιιιιιιϊ_ιιι___f_____iϊi__f ________ * 8& #i###################iii#######i#iii########_ι###_ι##i###i### iSoioioloioSoSoiiiiiiiiiiiiiiiiiiiliiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii; I iiillliiiiililiiilliiiiliiiiiliiililiililiiliiliiiiillllili II ώ u sss o iSSS ΪSSξ !__________§§8liiii888__8SS8-S8888__8_S88S88888888888__SSl88S8SS 8BS66 °°f Slsl 11° 5 SS SS S§ gg gsg SllSg Ssa °?§sssa Rs* as Is °° !.§§ sgsss 888 88SS °°R 8 00 β g s§ . i. °fi° i s ! sE se i! > .'-.i8iS8li8i-iSi8lSI .ggggssggggg. . j 1o11=1=o_1=_1=B1S1IS11Io1o1oIo1SoS1§o1o§ ___?___ ___ ' ______l_sss£S£sssgs a aaas SSSSsaϊ_S--SS3SSΪ_B3gssr 1 sSΪBS_SSSS88S8SSgS8S > mmm mii mmmmmm § I iiii!!!iii!ii!!iiii!_!!!i____I__i!!!! 5 oo _ _ _ = = oo„o = _ _oo = = o_ - ooo_ _ _ o = = o = = = = _ = _ ___s____gs_g___________s_____-_______ s 1111 ϊ . , 6 = o o o 5 t I S 1888 _ 5 _ 5 i !§!!!§§§!§!" o c !K8ϊ! ;_ _8«Ϊ ! 8 __! II $;. ϊ¥. S. ¥5 ;. ¥. ϊ¥S ggggggggggggggggggggggggggg,. III ≡Vfff≠ -IlϋϊHΪHl o c d _d ddddddddddc <i^ddcd 4 44444444444444 t ««I <i«;: S^8£Z/Z,6S_l/ID-f 9ST6Z/86 OΛV __ o oooooooooooooooooooooo ooooooo oooooo oooooooooo o ooo ooooooooooooo.oo ooooo oo ooo oooo o oo ooo ooooooooooooo o oooooooooooooooooooooooo αo oo o oooo o o o o o o ooo oooo o oo oooo ooo oo o 5 CM o oooooooooooσooo 5 m c o ^ 0 _ _ * . „. _- _ - ,- _ m ™ θ τ- f^ rt ^ . θ f^ α- θ) D ι- - rt ^τ ^ o r^ αι σ. g ^ ( rt ^ ui ϋϊ ^ __ θ- θ τ- ( rt 'q- -o tD _ > < r - π r t v « ω N © « ϊi ^ τ . -_ r . - τ - r. ^ ^ τ . ^ r ( M N r j r^ W ^ rt rt ( θ r ) rt r ) rt rt rt n ^ v 't V '. ' <r 3 Q o £L (D OT ^ OI W k W M ^ O « ro |(τi (r ι _. U M J θ Φ ' T , W W , J ^ ^ ω ffl ^ W Λ W M __ __ _3 __ 3 3 D ) -3 -- -- 3 _- α __ __ D 3 -- =J ;:] :, :: ' ::] 3 :, =, = ' - , o o o o π o o o o o o n S<5 Oo o o O o o O o o O σ' o O O σ o o σ σ o o o ■ σ o _, o α 2g o_39o 922 _> o o o o Oo Oo Oσ o o oo oo o ' o o o σ O o o ό oo o oσ o O OO O o oσ σ O OO OO OO OO O O O O O O ¬ σ o o o σ σ o o O O O O ^ < _ o o o o o o o o o o O O o o oo o o σ σ σ o σ o o o o σ oO oO O O O O O O O O O O ~ O O o oo o O O O O O O o Oo oO O O _ σ O- σ O- O O o Oσ O O O- o o oO O ' oO_ O O σ H O O O O O O O O O O O p o p o σ σ σ σ p σ o o o o o o o o o o o oσ oo og oσ oσ po σo σ■ o σ σ σ o o o o σ o σ o o o o o o o o o o o σ o o o o o o σ o o o oo o oo σo o o o 22ό o2 O < o_- _- _- 22 _- _- σ o σ σ o o o o σ o o σ o σ σ σ σ 2σ99o o22ό o2ό__o2σ o o O O O O o o σ o o o o o o σ σ o r- 1 o _ oo o o oo oo oo σo oo σo oo OO OO O O O O OO OO O OO O O OO O 1 OO OO O O OO '' s ε O C _ en r- M o o o o _ >< ω ≥ S 5 — — ._ — — -_ ■ ,n .n ,„ m >. ™ y, l1 ) U U - 1 ID l W o o o o σ σ σ σ σ o c S : CD 3 •_ Sfr8€r/_.6Sr_/JD€l 9ST6Z/86 OΛV (0 CM o o S _ a. .A ^ n S S? D. si -n -. .— cn θ -. ιn u- σ> -θ r o α. r. o ir t oo r r - t^ m co crto or ^ σ> *- _y (o_ t r o — _-o- - cCo r N r α. rm— t —o I_> o o o o o o o o o o o o o o o o ". g _ p iUfl iΛD i(θD αo. Nιo ωD ioD αu.- No (θα oo. or~ rT- iιΛ-- Nr-- -r--. ro. 'eiDr icno CD C CN IT) cn —> o r. CL O o o r. o o o o o n r. o o o o o o o o o o o o o o o o S OUJ-526-.xls OUJ-526 Born 2_95 DAY DATE Vol WEIGHT HEMATO- TREATMENT PARAMETERS T-8 Gr CRIT-% DEVICE FREQ MHz TIME FREQ MHz TIME FREQ MHz TIME POWER DEVICE 1 26-Ocl ooooo 2763 45 NO TREATMENT NO TREATMENT 2 29-Oct ooooo 2775 NO TREATMENT NO TREATMENT 3 30-Oct ooooo 27 92 NO TREATMENT NO TREATMENT 4 31-Oct ooooo 2747 NO TREATMENT NO TREATMENT 5 1-Nov ooooo 27 58 NO TREATMENT NO TREATMENT ε 2-Nov ooooo 27 44 NO TREATMENT NO TREATMENT 7 3-Nov ooooo 27 57 NO TREATMENT NO TREATMENT ε 4-Nov ooooo 28 07 45 NO TREATMENT NO TREATMENT 9 5-Nov ooooo 28 50 NO TREATMENT NO TREATMENT 10 6-Nov ooooo 28 92 NO TREATMENT NO TREATMENT 11 7-Nov ooooo 28 71 NO TREATMENT NO TREATMENT 12 8-Nov 28 76 NO TREATMENT NO TREATMENT 13 9-Nov 28 63 NO TREATMENT NO TREATMENT 14 10-Nov 27 82 NO TREATMENT NO TREATMENT 15 11-Nov 28 16 46 NO TREATMENT NO TREATMENT 16 12-Nov 27 90 NO TREATMENT NO TREATMENT 17 13-No. 27 73 NO TREATMENT NO TREATMENT 18 14-Nov 27 88 NO TREATMENT NO TREATMENT 19 15-Nov 27 51 NO TREATMENT NO TREATMENT 20 16-Nov 27 56 NO TREATMENT NO TREATMENT 21 17-Nov ooooo 2771 NO TREATMENT NO TREATMENT 22 18-Nov ooooo 27 56 43 NO TREATMENT NO TREATMENT 23 19-Nov ooooo 27 90 NO TREATMENT NO TREATMENT 24 20-Nov ooooo 26 25 NO TREATMENT NO TREATMENT 25 21-Nov ooooo 28 37 NO TREATMENT NO TREATMENT 26 22-Nov ooooo 27 35 NO TREATMENT NO TREATMENT 27 23-Nov ooooo 27 30 NO TREATMENT NO TREATMENT 28 24-Nov ooooo 27 24 8662A 43322485 0 1 Hr 43351871 0 1 Hr O O dBm Type ..p. 29 25-Nov ooooo 27 09 38 8662A 43322485 0 1 Hr 43351871 0 1 Hr 0 O dBm Type ..p. 30 26-Nov ooooo 27 58 31 27-Nov ooooo 28 08 8662A 43351853 0 1 Hr 43351871 0 1 Hr 0 0 dBm Type ..p., 32 28-Nov ooooo 28 43 8662A 43351853 0 1 Hr 43351871 0 1 Hr 3 O Bm Type ..p. 33 29-Nov ooooo 26 80 8662A 43346000 0 2 Hr 3 O dBm Type • p. 34 30-Nov ooooo 27 80 8662A 43353850 0 2 Hr O O Bm Type .. p .. 35 1-Dec ooooo 27 94 8662A 43346000 0 1 Hr 43353850 0 1Hr 0 0 dBm Type ..p.. 36 2-Dec ooooo 28 20 8662A 43346000 0 1 Hr 433538500 1Hr O O dBm Type ..p.. 37 3-Dec ooooo 26 40 38 4-Dec ooooo 28 60 45 6662A 43351830 0 2 Hr O O dBm Type -p.. 39 5-Dec ooooo 28 36 8662A 43351830 0 2 Hr O O dBm Type ' ..p.. 40 6-Dec ooooo 2S 05 8662A 43351830 0 0 O Bm Type 1 -p. 41 7-Dec ooooo 27 81 8662A 43351850 0 0 0 dBm Type ' 'p.. 42 8-Dec ooooo 26 17 8662A 43351830 0 O O dBm Type ' • p. 43 9-Dec ooooo 2B 90 43 8662A 43351830 0 O O dBm Type ' •p- 44 10-Dec ooooo 26 40 45 11 -Dec 27 B6 86S2A 43351830 0 O O dBm Type ' .p.. 46 12-Dec 2 * 91 8662A 43351630 0 2 Hr O O Bm Type ' .p.. /11/97 Page 5 OUJ-526- xls OUJ-526-.xls POWER ooooo ooooo ooooo ooooo ooooo 22-Dec ooooo 24-Dec ooooo 25-Dec ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo ooooo Type "R" ooooo ooooo 23-Jan ooooo ooooo ooooo ooooo ooooo ooooo ooooo 3 0 dBm Type "S" /11/97 Page 6 OUJ-526- xls OUJ-526-.xls DEVICE ooooo OOdBm Typ "P" OO Bm Type "P" OOdBm Type "P" ooooo OOdBm Type "P" OO Bm Type "P' ooooo 0 OdBm Type "P" ooooo OOdBm Type "P" ooooo OO Bm Type "P" ooooo OOdBm Type "P' ooooo 0 O Bm Type "P" ooooo ooooo ooooo OO Bm Type "P" ooooo OOdBm Type "Q * ooooo OOdBm Type "Q" ooooo OOdBm Type "Q" ooooo OOdBm Type "0" ooooo ooooo OOdBm Type "Q" OOdBm Type "Q" OO Bm Type "Q' ooooo OO Bm Type "0" ooooo 00 dBm Type "R' ooooo OOdBm Type "R' ooooo ooooo 00 dBm Type "R' ooooo 00 dBm Type "R' ooooo OOdBm Type "R' ooooo OOdBm Type "R' ooooo 0 O Bm Type "R' ooooo 0 O Bm Type "R" ooooo ooooo 00 dBm Type ' R' ooooo 00 dBm Type "R ooooo OOdBm Type "R' ooooo OOdBm Type -R' ooooo OO Bm Type "R' ooooo OOdBm Type "S' ooooo ooooo D D dBm Type "S" ooooo OOdBm Type "S" ooooo OOdBm Type _' ooooo OOdBm Type "S" ooooo OOdBm Type "S ' ooooo OO Bm Type "S" ooooo ooooo 30 dBm Type "S" /11/97 Page 6 OUJ-526- xls OUJ-526-.xls DATE Vol WEIGHT HEMATO- TREATMENT PARAMETERS T-6 Gr CRIT-% DEVICE FREQ MHz TIME FREQ MHz TIME FREQ MHz TIME POWER DEVICE 95 30-Jan 00000 2667 8662A 433518700 2Hr 3 OdBm Type "S" 96 31-Jan ooooo 2629 8662A 433518500 2Hr 3 O Bm Type "S" 97 1-Feb 2673 8662A 433518300 2Hr 3 OdBm Type "S" 2-Feb ooooo 2719 8662A 433518500 2Hr 30 dBm Type "S" 3-Feb 2719 8662A 433518300 2 Hr 3 OdBm Type "S" 100 4-Feb 2720 5-Feb ooooo 2721 8662A 433518700 2Hr 30 dBm Type ' S" 102 6-Feb ooooo 2757 8662A 433518300 2Hr 3 OdBm Type "S" 103 7-Feb ooooo 2794 8662A 433518300 2Hr 3 O Bm Type "S" 8-Feb ooooo 2848 8662A 433518700 2Hr 3 OdBm Type "S" 9-Feb OODOO 2705 8662A 433518700 2Hr 3 OdBm Type "S" 10-Feb ooooo 2766 8662A 3 OdBm Type "S" 11-Feb ooooo 2768 12-Feb ooooo 2771 8662A 433518500 1 Hr 1 Hr 3 OdBm Type "S" 13-Feb ooooo 2795 6662A 433516500 1 Hr 3 OdBm Type "S" 4-Feb ooooo 2832 8662A 433518710 2Hr 30 dBm Type "S" 15-Feb OODOO 2829 8662A 433518500 1 Hr 433518530 1 Hr 3 OdBm Type "S" 112 16-Feb ooooo 2774 8662A 433518500 1 Hr 433518530 1 Hr 3 O Bm Type "S" 113 17-Feb ooooo 2753 8662A 433518500 2Hr 433518530 1 Hr 30 dBm Type "S" 114 18-Feb ooooo 2825 19-Feb ooooo 2900 8662A 433518500 1 Hr 43351B530 1 Hr 3 OdBm Type T" 20-Feb ooooo 2807 8662A 433518530 2Hr 433518710 1 Hr 3 OdBm Type "T" 21-Feb ooooo 2708 8662A 433518530 2Hr 433518710 1 Hr 0 OdBm Type T 22-Feb ooooo 2796 8662A 433518530 1 Hr 433518710 2Hr OOdBm Type "T" 23-Feb OOODO 2675 8662A 433616700 3Hr 0 OdBm Type T' 120 24-Feb ooooo 2708 8662A 433518700 3Hr OOdBm Type "T 121 25-Feb ooooo 2780 122 26-Feb ooooo 2650 8662A 433518500 3Hr OOdBm Type T" 27-Feb ooooo 2761 8662A 433518530 1 Hr 2Hr OOdBm Type T 28-Feb ooooo 2787 8662A 433224850 1 Hr 433460000 2Hr OOdBm Type "T 29-Feb ooooo 2765 8662A 433224850 1 Hr 433460000 2Hr OOdBm Type T" 126 i-Mar ooooo 2709 8662A 433224850 1 Hr 433460000 2Hr 0 O Bm Type "T" 127 2-Mar ooooo 2695 8662A 433224850 1 Hr 433538000 2Hr OO Bm Type "T 128 3-Mar OODOO 2675 129 4-Mar DOOOO 2658 8662A 433224850 1 Hr 433538000 2Hr 0 OdBm Type ' T 130 5-Mar OOOOO 2792 8662A 433224850 1 Hr 433460000 1 Hr 433538500 1 Hr 00 dBm Type "U" 6-Mar OOODO 2744 8662A 433224850 1 Hr 433460000 1 Hr 433538500 1 Hr OOdBm Type "U' 7-Mar ooooo 2784 8662A 433518530 2Hr 433518710 1 Hr 0 O Bm Type "IT 133 8-Mar ooooo 2746 8662A 433518530 2Hr 433S18710 1 Hr OOdBm Type "U" 134 9-Mar ooooo 2B75 8662A 433224850 1 Hr 433460000 2Hr OOdBm Type "V" 135 10-Mar ooooo 2765 136 11-Mar ooooo 2755 8662A 433224800 1 Hr 433224850 1 Hr 1 Hr 0 OdBm Type "V" 12-Mar ooooo 2762 86E2A 433460000 3Hr OOdBm Type "U" 13-Mar ooooo 2827 8662A 433460000 3Hr 0 OdBm Type U' 14-Mar OOODO 2833 B662A 433460000 3Hr 00 dBm Type "U" 15-Mar ooooo 2859 8662A 433518530 2Hr OO Bm Type "U" 141 16-Mar OOOOD 2835 8662A 433460000 OOdBm Type "U" 142 17-Mar OOOOO 2836 OO Bm Type "U" /11/97 Page 7 OUJ-526- xls OUJ-526-.xls DAY DATE Vol WEIGHT HEMATO- T-6 TREATMENT PARAMETERS Gr CRIT-% DEVICE FREQ MHz 143 TIME 1B-Mar FREQ MHz 00060 TIME FREQ MHz 2838 TIME POWER 8662A 433224800 DEVICE 144 1Hr 19-Mar 00076 433538000 2Hr 2779 OOdBm 8662A Type -U- 433224800 145 1 Hr 20-Mar 433460000 1 Hr 0OD88 433538000 IHr 2798 OOdBm 8662A Type "U" 146 21-Mar 433518530 2Hr 00100 2837 OOdBm B662A Type "U" 147 22-Mar 433518530 3Hr 00112 2841 OOdBm 8662A Type "U" 14B 23-Mar 433460000 3Hr 00151 2B60 31 OOdBm 8662A Type "IT 149 24-Mar 433224850 00151 433538000 1 Hr 2890 OOdBm Type "U" 150 25-Mar 00159 2912 8662A 151 26-Mar 433224850 2Hr 00185 43353BO00 1 Hr 2875 OOdBm 8662A Type "IT 152 27-Mar 433518700 1 Hr 433518710 00193 2Hr 2858 OO Bm 8662A Type "IT 153 2B-Mar 433460000 1 Hr 00228 433518710 2887 2Hr OOdBm 8662A Type "IT 154 29-Mar 433460000 1 Hr 00218 433518710 2Hr 2879 OOdBm 8662A Type -U" 155 30-Mar 433460000 3Hr 00218 2930 36 OOdBm 8662A Type "U" 156 31 -Mar 433460000 3Hr 00218 2960 OO Bm Type "U" 157 1-Apr 00242 2985 8662A 158 2-Apr 433224850 2Hr 00265 43353B000 3013 1 Hr OOdBm 8662A Type "IT 159 3-Apr 00276 433518710 3003 3Hr 00 dBm 8662A Type "U" 160 4-Apr 00289 433518530 3Hr 2917 OOdBm 8662A Type "U" 161 433224920 5-Apr 1 Hr 433460900 1 Hr 00332 2908 OOdBm 8662A Type "U- 162 433224920 1 Hr 6-Apr 433460900 00347 1 Hr 2959 34 OOdBm B662A Type "IT 163 433225520 7-Apr 2 Hr 00347 3000 OO Bm Type "U" 164 8-Apr 00424 3D 45 8662A 165 433224920 9-Apr 1 Hr 00495 433460900 1 Hr 43351B530 1 Hr 3068 OOdBm B662A Type "U" 166 433224920 10-Apr 1 Hr 433460000 00514 1 Hr 43351B710 3159 1 Hr OOdBm 8662A Type "U" 167 433224920 11 -Apr 1 Hr 433460900 00534 2Hr 3187 OOdBm 8662A Type "U" 168 12-Apr #VALUE' OOdBm B662A Type "U" OOdBm Type "U" /11/97 Page 8 OUJ-526- xls . .. . . . . . . . . . . P. .. ... .. . . . . . . . . . . . . .. i » ..i » . ! » i > . . « £ . 66 . 6 . 6 666666 6666 6666666 666666 666666 666666 66666 . 6 6666 . 66 6 . 6 . 666 „„__ ϋjut .m... miiii Him imii sum 111 11 E E E E E E SΠS ___: Λ A I I 111! 'iiiii iiiiii ii lllll mn nm ss Ii !. ...... ...... ...... ...... ...... .... 1 . 6 . 6 . 6 . 6 . 6 . 6 . 6 666666 6666.6 . 66 66 . 6 . 6 . 6 . 6 . 6 .6 . 6 . 6.6 __ x Hi! ______ li.iiϊ ____ _ iiiiii iiir iiiϊϊf I iiiiii iiiiii lllll i ° . iϊS8SRSSSS_SKS: :αssss; IRRftKKi.;. K88KKK. n O .ΞBooSo Ξoo δo! i _ S _ 88 g s s s ε S S g J 188 88_Sll_ i8li8Slg_8___J sssssssssss: : g gg ii 8! 1888188! _ϊ APPENDICES B1-B10 CONTROL MOUSE DATA Index tPapes numbered on hack) Appendix Subject Pages Bl A 486 95-97 B2 A 488 98-100 B3 A 490 101-102 B4 A 492 103-105 B5 A 500 106 B6 A 538 107-108 B7 A 540 109-110 B8 A 542 111-112 B9 A 592 113 BIO A 594 114 Surbeck. el al , Therapeutic Apparalus and Method v mmu)U) U)N N fflaio. m(O N Λ t. r OO OO OO OO OO OO OO O O O O O OO OO O O O O O O OO OO O OO OO O O O O O O OO O OO O O O OO O O O O O O O OO O O O O O O O O O O OO OO O O O O o o o o O O O O O O O O O OO OO OO OO O o ._. o o o o o o oo oo o O O O O o o o o o o O O O O O OO OO OO OO OO OO OO OO OO OO OO OO OO OO O O O O O O O o o o _ o O , o o o o oo σ o oo . O O O O O O O O O O O O O O O O O O > a) a o ω ω 5 <<<<<<<< <<<< <<< << 5= a "" 58 z z z z z z z z ooόόόooό d όoόόbόόσbόόooooooσoooo ααααaααααaααααaαααααaα a α ji aa fl α a fl - σ * _ ■ s s s Όω ,„ » > i. o σ> π > < ω t Sfr 8£Z/L6SΛJlDd 9SΪ6Z/86 OΛV A-486-DA.xls T-1 AVERAGE GROWTH T-2 AVERAGE GROWTH 0486 0 505 0 380 0 112 0 026 0 026 0 026 0000 00 Prepared by Bob DeVries 4/11/97 Page 3 |sS2. SSRI_SΪS. S_ΪSS. SRS. . _S?-g_. SS?_. _; . _!!!_s;s_ . s_ϊ; " gSSSΪ_SSSSS3_»_S8R5S_S_I.SIl!_πSSS_SSli!I.SiSI.8SSSS8gSss _ IIII1I1IISII1I11II111I1I11I1III1III1I11I1IIIII11I N Ύ S § 8 S « δ 5 § § s s s s s § g <§ _ 8 § s § lliiliii lllll I < * iiiiiiϊiϊϊiiiiiiiiϊiiiiϊiiiiiiiiiiiiiiiiiiiiiiiii ! 0) i 881IIII-11 -II 8888ϊ888__8ϊ §ϊ §§ §_ s8 §8 §s §8 a§ §8 §8 §§ i 1 §1118188S886 ° ° ililsifftias . < § § § & S B 1 & B 1 B B B I 1 S S B I B I & § § I § B i B I § § I I § § § § § § § § I ? f g I § S ......... Λ » » » . . o r » 5 ; ; S |. ι 5 ; o r i; n < ..[. j . θ r n n , « W o o o o α o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o r_ δ Q < φ ra D- ω A-488-DA xls 101 0150 0110 102 0150 ooooo 103 ooooo 0160 104 ooooo 0190 ooooo 105 ooooo 0250 ooooo 106 ooooo 0250 ooooo 107 ooooo 0250 ooooo 108 ooooo 0250 ooooo 109 ooooo 0250 ooooo 110 ooooo 0250 ooooo 111 ooooo 0250 112 ooooo 0250 113 ooooo 0280 114 0280 115 02B0 116 0280 117 DIED 11/139! DIED 11 139S DJED 11 139S T-1 AVERAGE GROWTH T-2 AVERAGE GROWTH T-3 AVERAGE GROWTH 0119 0116 Prepared by Bob DeVries 4/11/97 Page 3 ___ 5 < *- «- o O o o o o o o o o o o o o o o o o o α o o o o o o o o o o o o o o o o o o o o o o o o o o o α o o o o o o o o o o o o Wm N_o Nm lNm N-o Ni oo oo oo oo oo oo oo oo o oΩ o oo oo αo oo oo oo oo o O oO oO oO oO oO o Q oO oO oO oO oO oO oO oO oO oO oO oO oO oO oO o oO O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O — O O O O O O O O O O O O O O O O O O i O O O O O O O O O O O O O O O O O O O < a> a Q < H a. Q 2- or ^i o_o o-n o_n or ^ on o oo o ^o oo oc o o o i n oto oo ov mto oc_i o-- oo coo co. o ou_ σc__ oo oto o-T o"i o^ o , * oo l o*o oo oo oo o( ω Q ^ o o o δ o δ o o o o o o o o o o o o o ^ ^ ^ ^ ^ ^ ^ ^ ^ -- -- ^ -- ^ -- τ- ^ ^ τ- ^ : O A-490-DA xls 11/28/95 0850 0850 0550 20S03 0520 0350 0310 3935 112995 Died 112995 HVAIUE' Died 11/29/95 3988 Prepared by Bob DeVries 4/11/97 Page 2 to . o o o o o L >U oo oo oo oo oo o o o o o o o o o o o o o o o o o o o o o o o o o o o o 7 0 o u in in m in in r- co ι- ι~- ι- r- r~ σ> o co r- r- r-. co <o *- o o o o £ a: o o o o o o o o o o o o o α o o o o o o o o o o s. _ < o o o o o o m o v r— r- r-- r-- -θ θ io -τ u" u"i to -j' W> -*^ x» i o o o o o o o o o o o o o o o o o ι ^ r^ r ^ -- -- ι co f ^ r ^ r ^ r ^ r ^ co co -- -- ~ ^- - »- - -- o o c_t _» o o o o o Jx O _s oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oσ oo oo oo oo oo oσ oo Qj > o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o _. o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o N o o o o o o o o o o o o o o o o o o o o o o ω L — S °" I- _J 7 ii o-~ τo- ro- cm M fo-- fα«- ro-- ho- ro- -o- -o- -o- o-- o-- -o- ^o- oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo σo oo oo oo oo oo oo oo oo oo oo oo oo oo * o o o o o o o o o o o o o o o o o o o o o o o o o o o o U >-* J oo oo oo o oo o o o oo oo oo o oo o o oo o oo oo o oo oo o oo oo o o o o oo o o o o o oo o o o o o o o o o o o o oo o oo oo o o o o oo oo oo oo oo oo oo ooo o o oo oo o o o oo oo oo oo o o oo oo " f- o o o o o o o o o o o o o o o o ___ < o o o o o o o o o o o o o o o o ___ <υ TO Q_ o o o o o o o o oo o o o o o o o o o o o o o o o o o o o oo o o o o o o o o o o o o o o o o o o o _ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o ro v o , o oO oo oo o oo o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o ω __2 X > < α> D _Q o o o o o ω < o o o o o o o o o ■ o ω Q- ω Z Z Z Z Z Z Z Z ^ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z ^ S S S S ^ S Q Q Q Q Q Q Q Q Q Q CI Q O Q c i n i « _ ι: » ι i S ; ϊ q ; ; ϊ t . . S ?; S _ s π n _ π ^ " ™ ' " » l - » li . . . . . . . . Ϊ . S S A-492-DA xls 99 22-DeC ooooo ooooo 0 590 0 510 0 370 05828 0720 0720 0 490 13298 3270 100 23-Dec ooooo ooooo 0 590 0 520 0 370 05943 0720 0 710 0490 13113 33 50 101 24 Dec ooooo ooooo 0 590 0 530 0 370 06057 0720 0710 04BO 12845 34 30 102 25-Dec ooooo ooooo 0 590 0 540 0 360 06004 0730 0700 0480 12B40 35 10 103 26-Dec ooooo ooooo 0 590 0 550 0360 06116 0730 0690 0470 12393 3590 104 27-Dec ooooo ooooo 0 580 0 550 0 360 06012 0730 0690 0470 12393 36 84 105 28-Dec Died 12/29/95 *VALUE' Died 12/29195 -VALUE' Died 12/29/95 #VALUE' Died 12/29/95 ALUE' T-1 AVERAGE GROWTH T-2 AVERAGE GROWTH T-3 A VERAGE GROWTH T-4 AVERAGE GROWTH 0 042 0 042 04B5 0506 0339 -t- Prepared by Bob DeVries 4/1 /97 Page 3 ra α_ υ a ^ O O O O O O O O O O O -- -- -- -- -- "- CM (N «- ι- τ- 5- s α α ft α α α α a α α α α α Q __ α„ „ w -- _ - -- „ -. 7' ti (/) t) ιo t Λ - t Λ ω (Λ ω /_ ϋ . w _ Λ Λ o o o o o o o o o o c _ _ _ _ _. Z Z Z Z Z Z Z Z zzzzzzzzz OOOOOOOOOOOOO ααα sz ααααα α α α O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o o σ σ • σ o o o o o o o o o o o o o σ o o o o o o σ o σ o σ σ rj o o σ o o o o o o o σ σ σ σ σ o o σ o σ ' σ o σ o o 3 O O O O o σ o o σ o σ σ o o σ o σ o o σ σ σ o o o o O O O OO OO OO O OO O O O OO OO σ o o o o o σ o σ o σ σ o σ σ o o o „ σ_-_ o_ _σ o o σ o o o o σ O σ O O o o O O o o O o O o O o o σ o σ o o o o σ o o o o o o o o O O O OO OO OO O OO OO OO o-_ _o-_ _o_. — O O O O O O O O O O O O O O O O O O O O O O o O ' O O OO O O OO O O OO OO OO OO OO O o O ' — ~ ™ ~ O™ Oo σO oO oO Oo Oo oO O O O O O O O O O O " " " SP8£Z/ 6SΩJlDd 9516Z/86 OΛV φ σ. ro α. y ».5 <2 ; ui a. S a oo _o_o_ o_oooooooo ooo σoo_ o_ _ o_ o_ σ_ o_ o_ ooooooooooo o oooooooo oo o oo . oo o ooooooooooooooooooooooooσooooo ooooooooooo "t _> X > < ω _ Q A-540-DA.xIs 49 Died 01/02/95 #VALUE' 50 T-1 AVERAGE GROWTH 0637 0 584 0413 0 119 o Prepared by Bob DeVries 4/11/97 Page 2 ω en ro Q. O 5 °> - 5 O oooooooooooooooooooooo Q TO z g e z z z z Qii Q Q_- Q __ __ o Q 9 ™ ™ ™ ™ ™ ™ ™ ™ ™ 7 ™ ™ ffl A-542-DA.xls 49 14-Jan 1 020 1 010 0620 33437 0780 0600 0450 11025 40 70 50 15- Jan 1 050 1 010 0620 34421 0840 0610 0450 12071 41 65 51 16- Jan 1 040 0 970 0620 32743 0830 0 640 0460 12792 4240 52 17-Jaπ 1 040 0 990 0 580 31262 0 870 0 640 0470 13700 40 85 30 53 18-Jaπ D ed 1/18/95 #VALUEI Died 1/18/96 #VALUEI 54 19-Jaπ T-1 AVERAGE GROWTH T-2 AVERAGE GROWTH 55 20-Jan 0803 0897 0536 0226 0401 0424 0284 0034 Prepared by Bob DeVries 4/11/97 Page 2 ra Q- ii' S - ooooooooo oαooooooooooooooooooσoooooθooι_: o o o c- o o o o o o o o o o α o o o o o o o o o < Q o o o o o o o o o o o o o o o o o o o o o o o o cn LO o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o * T-ooooooo Hooooooo oooooooooo »ooo)θi(»oιo- --Nn oooooo------------ rf Ol "? -? " ? "? "? "? -? "? "? -? "? -? "? -? "? '? ! ω ffl _- C_ o-. - r -- -.N. t-o. v τ . i-n. i-o- r-- c-o _-i ofvι -c-. f.N. tro. ' A-594-DA xls DAY DATE X Y z EVOL Y EVOL WEIGHT HE DOB 6/27/95 A-594 RT SIDE T-1 A-594 T-2 GRAMS CT 1 0160 0200 0090 00151 00000 41 92 2 0200 0210 0090 00198 00000 41 40 3 0240 0220 0100 00276 00000 40 80 4 0270 0230 0100 00325 ooooo 40 20 5 0270 0220 0090 00280 ooooo 39 95 6 0280 0230 0100 00337 ooooo 39 73 7 0260 0240 0110 00359 ooooo 3949 8 0280 0280 0140 00575 ooooo 3960 9 0300 0260 0150 00660 ooooo 39 10 10 0340 0290 0150 00774 ooooo 38 50 11 0360 0290 0160 00874 ooooo 38 06 12 0390 0300 0230 01409 ooooo 13 0450 0340 0240 01922 ooooo 14 0460 0360 0260 02254 ooooo 15 0500 0390 0290 02960 ooooo 16 0520 0420 0290 03316 ooooo 17 0530 0440 0290 03540 ooooo 18 0550 0470 0290 03924 ooooo 19 0560 0490 0290 04166 ooooo 20 0590 0530 0340 05566 ooooo 2! 0640 0570 0340 06493 ooooo 22 0670 0610 0360 07702 ooooo 23 0700 0640 0370 0B678 ooooo 24 0740 0670 0360 09344 ooooo 25 0790 0700 0360 10422 ooooo 26 0860 0790 0300 10670 ooooo 27 0920 0940 0340 15393 ooooo 28 1020 1010 0290 15640 ooooo 29 1030 1030 0290 16106 ooooo 30 1050 1050 0280 16160 ooooo 31 1060 1070 0280 16625 ooooo 32 1070 1080 0280 16939 ooooo 33 1110 1060 0310 19094 ooooo 34 1110 1100 0270 17258 ooooo 35 1170 1090 0270 18026 ooooo 3431 36 Died 2/16/9t HfVALUEI ooooo Prepared by Bob DeVries 4/11/97 Page 1 APPENDIX C TREATED MOUSE DATA (EXTERNAL MODULATOR EMBODIMENT) Index (Pages numbered on hack) Appendix Subject Pages Cl OUJ-738 1 16 Surbeck, el al , Therapeutic Apparatus and Method OUJ-738-DATA - /Ϊ- & UJ-738 Born First tumor appeared on 3/5/97 Device Code: SW & HP' -Short Wire and Homer's Pυlser Device Code: SW & NP'Short Wire and New Pulser DAY DATE T-l Lt Underarm Vol WEIGHT HEMATO- TREATMENT PARAMETERS Ln Wd Ht T-1 Gr cp.rr-% DEVICE FREQ MHz POWER TIME FREQ MHz POWER TIME DEVICE 1 5-Mar 0.1 10 0.1 10 0.1 10 .00070 37.95 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 2 6-Mar 0.1 10 0.1 10 0.1 10 .00070 36.83 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 3 7-Mar 0.100 0.1 10 0.100 .00058 36.00 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 4 8-Mar 0.1 10 0.100 0.100 .00058 36.02 46 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 5 9-Mar 0.1 10 0.100 0.100 .00058 36.25 NO TREATMENT NO TREATMENT 6 10-Mar 0.100 0.100 0.100 .00052 36.56 8662A 43351855.0 43353800.0 0.0 dBm 1. SW & NP 7 1 1 -Mar 0.1 10 0.100 0.090 .00052 35.32 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & NP 8 12-Mar 0.1 10 0.110 0.080 .00051 34.88 8662A 43346000.0 43353800.0 0.0 dBm 1 , SW & NP 9 13-Mar 0.120 0.120 0.070 .00053 35.1 1 8662A 43351855.0 43346000.0 0.0 dBm 1 , SW & NP 10 14-Mar 0.130 0.120 0.070 .00057 34.91 8662A 43351855.0 43353BOO.O 0.0 dBm 1 , SW & NP 1 1 15-Mar 0.140 0.130 0.060 .00057 34.84 44 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 12 16-Mar 0.145 0.130 0.065 .00064 35.20 NO TREATMENT NO TREATMENT 13 17-Mar 0.150 0.130 0.070 .00071 35.58 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW S HP 14 18-Mar 0.150 0.130 0.070 .00071 35.25 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 15 19-Mar 0.150 0.120 0.070 .00066 33.66 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 16 20-Mar 0.160 0.120 0.070 .00070 33.81 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 17 21 -Mar 0.160 0.120 0.070 .00070 32.67 8662A 43351855.0 43353800.0 0.0 dBm 1. SW & HP 18 22-Mar 0.160 0.130 0.070 .00076 32.83 43 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 19 23-Mar 0.160 0.130 0.070 .00076 33.23 NO TREATMENT NO TREATMENT 20 24-Mar 0.170 0.130 0.080 .00093 33.63 8662A 43351855.0 43353800.0 "-40 dBm 1 , 1 SW & HP 21 25-Mar 0.180 0.130 0.080 .00098 33.01 8662A 43351855.0 43353800.0 "-50 dBm 1 , SW & HP 22 26-Mar 0.190 0.130 0.070 .00091 32.69 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 23 27-Mar 0.190 0.130 0.080 .00103 31.25 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 24 28-Mar 0.190 0.130 0.080 .00103 31.63 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 25 29-Mar 0.190 0.130 0.080 .00103 31.1 1 44 8662A 43351855.0 43353800.0 0.0 dBm 1 , SW & HP 26 30-Mar 0.190 0.130 0.080 .00103 31.36 NO TREATMENT NO TREATMENT 27 31 -Mar 0.200 0.130 0.070 .00095 31.64 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 28 1 -Apr 0.210 0.130 0.070 .00100 31.83 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 29 2-Apr 0.210 0.130 0.070 .00100 31.1 1 8662A 43351855.0 433538OO.0 0.0 dBm 1 , 1 SW & HP 30 3-Apr 0.210 0.140 0.070 .00108 31.80 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 31 4-Apr 0.220 0.140 0.080 .00129 30.98 8662A 43351855.0 43353800.0 0.0 dBm 1 , 1 SW & HP 32 5-Apr .00000 NO TREATMENT NO TREATMENT 33 6-Apr .00000 4/7/97 Page 1 OUJ-738-DATA

Claims: CLAIMS We claim: 1. Therapeutic apparatus, comprising means for generating an approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz., a quartz crystal with a resonant frequency in the radio frequency range, serially driven by said signal, a wire loop, the input of which is serially driven by the output of said quartz crystal, and the other end of which is grounded with respect to said square wave generating means. 2. The apparatus of claim 1, wherein the frequency of the crystal is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ± 20 Hz. 3. The apparatus of claim 1, wherein the means for generating said approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz. comprises means for generating a first square wave of approximately 60 Hz., at a duty cycle of approxi- mately 50%, means for generating a second square wave of approximately 1.167 Hz., at a duty cycle of approximately 50%, and means for ANDing said first square wave and said second square wave. 4. The apparatus of claim 3, wherein between said ANDing means and said crystal there is inserted a series LC filtering means comprising an inductor and a variable capacitor. 5. The apparatus of claim 4, wherein said wire loop is made from approximately five turns spaced approximately 3.175 mm. apart of a wire approximately 60 cm. long. 6. The apparatus of claim 5, wherein said wire loop is mounted on the housing of the apparatus. 7. The apparatus of claim 6, wherein the power supply for the apparatus comprises a battery housed within the apparatus so as to render the apparatus self-contained. 8. The apparatus of claim 6, wherein the power supply for the apparatus comprises an external, power line driven transformer. 9. Therapeutic apparatus, comprising, a stable frequency generator means having a modulation input, a range of radio frequency outputs, the ability to provide output at a steady power of 1 mw or less, and the ability to pro- vide radio frequency output tunable to at least one half a part per million, a modulator, connected to said modulation input, providing an approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz., and a wire loop, one end of which is connected to the output of said frequency generator means, and the other end of which is grounded with respect to said frequency generator means. 10. The apparatus of claim 9, wherein said radio frequency output is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ± 20 Hz. 11. The apparatus of claim 9, wherein said modulator comprises means for generating a first square wave of approximately 60 Hz. at a duty cycle of approxi- mately 50%, means for generating a second square wave of approximately 1.167 Hz. at a duty cycle of approximately 50%, and means for ANDing said first square wave and said second square wave. 12. Therapeutic apparatus, comprising, a stable frequency generator means having a range of radio frequency outputs, the ability to provide output at a steady power of 1 mw or less, and the ability to provide radio frequency output tunable to at least one half a part per million, a modulator, connected in series to the radio frequency output of said modulation input, pro- viding an approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz., and a wire loop, one end of which is connected to the output of said frequency generator means, and the other end of which is grounded with respect to said frequency generator means. 13. The apparatus of claim 12, wherein said radio frequency output is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Liz., 43,346,090 Liz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Liz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ± 20 Hz. 14. The apparatus of claim 12, wherein said modulator comprises means for generating a first square wave of approximately 60 Hz. at a duty cycle of approximately 50%, means for generating a second square wave of approximately 1.167 Hz. at a duty cycle of approximately 50%, means for ANDing said first square wave and said second square wave, and means responsive to said ANDed first and second square wave for switching a series radio frequency signal. 15. The apparatus of claim 12 wherein, said wire loop is connected to the output of said frequency generator means by a Hewlett-Packard 10501 A or equivalent shielded coaxial cable. 16. A method for treating cancer and other illnesses in a human or animal subject, comprising, generating a radio frequency signal tuned to a treatment frequency that has been specified to a precision of at least one half of a part per million; modulating said radio frequency with an approximately 60 Hz. square wave with an approximately 50% duty cycle which has been gated by an approximately 1.167 Hz. square wave with an approximately 50% duty cycle applying said modulated radio frequency signal at a power of 1 mw or less to one end of a wire loop and grounding the other end of said loop, placing said wire loop to which said modulated radio frequency signal has been applied on the sur- face of the subject's body for a period of at least one hour. 17. The method of claim 16, wherein said radio frequency is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Liz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Liz., all ± 20 Hz. 18. The method of claim 16, wherein said wire loop is made from approximately five turns spaced approximately 3.175 cm. apart of a wire approximately 60 cm. long 19. A low power, precisely tuned, stable RF generator comprising, means for generating a sequence of audio frequency square waves, and a quartz crystal tuned to an RF frequency, connected in series to said square wave generating means.

Inventors: DEVRIES ROBERT L, SURBECK L HOMER DI, SURBECK MARGARET P, DEVRIES, ROBERT, L., SURBECK, L., HOMER +DI, SURBECK, MARGARET, P.
Applicants: DEVRIES ROBERT L, SURBECK MARGARET P, SURBECK MARGARET P & LF, DEVRIES, ROBERT, L., SURBECK, MARGARET, P., SURBECK, MARGARET, P. +LF
Application year: 1997
Main classification: A61N
IPC codes: A61N1, A61N2